

[HIV Home](#)

## Core Indicators for Monitoring the Ending the HIV Epidemic Initiative:

### National HIV Surveillance System Data Reported through December 2022; and Preexposure Prophylaxis (PrEP) Data Reported through September 2022

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for diagnoses of HIV infection reported to CDC through December 2022 and preexposure prophylaxis (PrEP) data reported through September 2022.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

### Suggested Citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative: National HIV Surveillance System data reported through December 2022; and preexposure prophylaxis (PrEP) data reported through September 2022. *HIV Surveillance Data Tables* 2022;3(4). <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>. Published May 2023. Accessed [date].

### Technical Notes



## Technical Notes

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and then by at least 90% by 2030. The included tables provide national-, state-, and county-level (EHE Phase I jurisdictions only; see Table 7) data for the 6 core indicators of the EHE initiative, which are the following:

- **New HIV infections:** the estimated number of new HIV infections in a calendar year.
- **Knowledge of HIV status:** the estimated percentage of persons with HIV who have received a diagnosis.
- **Diagnoses of HIV infection:** the number of HIV infections confirmed by laboratory or clinical evidence in a calendar year.
- **Linkage to HIV medical care:** the percentage of persons who have received a diagnosis of HIV infection in a calendar year and were linked to HIV medical care within 1 month.
- **HIV viral suppression:** the percentage of persons living with diagnosed HIV who have a suppressed viral load at the most recent test in a calendar year.
- **Preexposure prophylaxis (PrEP) coverage:** the percentage of the number of persons prescribed PrEP in a calendar year relative to the estimated number of persons with indications for PrEP in a calendar year.

The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress.

## Surveillance of HIV Infection

Data presented were reported (after the removal of personally identifiable information) to the CDC through December 31, 2022. Please use caution when interpreting the following:

- Data for the year 2020. Should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. [2–6].
- Data for the year 2022. Data provided using a National HIV Surveillance System (NHSS) dataset produced prior to reaching a 12-month reporting lag are considered preliminary.
- HIV incidence and prevalence estimates. Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the CD4+ T-lymphocyte (CD4)-based depletion model [7] to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. The original CD4-based model assumes stable testing and diagnosis trends during the period assessed. However, the COVID-19 pandemic caused both HIV testing [5, 6] and HIV diagnoses [8, 9] to deviate from recent trends. The monthly distribution of diagnoses occurring during 2020 and 2021 were adjusted to account for excess delay. See the Technical Notes of *Estimated HIV incidence and prevalence in the United States, 2017–2021* at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html> for additional information.
- Data on diagnoses of HIV infection. HIV surveillance reports may not be representative of all persons with HIV because not all infected persons have been (1) tested or (2) tested at a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing; the results of anonymous tests are not reported to the confidential, name-based HIV registries of state and local health departments. Therefore, reports of confidential test results may not represent all persons who tested positive for HIV infection.
- Deaths and prevalence-based data (HIV viral suppression) due to known delays in reporting of deaths to CDC.
- Numbers less than 12 and trends based on these numbers.

## Tabulation and Presentation of Data

### New HIV Infections (HIV Incidence)

New HIV infections among persons aged  $\geq 13$  years are estimated using the first CD4 test result after HIV diagnosis and a CD4-depletion model indicating disease progression or duration after infection (Tables 1a–c).

More information on estimating new HIV infections can be found at in the report *Estimated HIV incidence and prevalence in the United States, 2017–2021* at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>.

### Knowledge of HIV Status

The Knowledge of HIV Status indicator is measured as the percentage of persons aged  $\geq 13$  years with diagnosed HIV infection (Tables 2a–c). For this measure, the numerator (data reported to CDC) is the number of persons aged  $\geq 13$  years living with diagnosed HIV infection at the end of the year. The denominator, total HIV prevalence, is the estimated number of persons aged  $\geq 13$  years living with HIV infection (diagnosed or undiagnosed) at the end of the year.

Knowledge of status and prevalence data for the year 2021 are preliminary and based on death data reported to CDC as of December 2022. The following areas had incomplete reporting of deaths for the year 2021, and prevalence estimates

should be interpreted with caution: Mississippi. Estimates for areas without laws requiring reporting of laboratory data, or with incomplete reporting of laboratory data to CDC, should also be interpreted with caution. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia County), and Puerto Rico.

More information on calculating HIV prevalence and percentage of persons with diagnosed HIV infection can be found in the report *Estimated HIV incidence and prevalence in the United States, 2017–2021* at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>.

## Diagnoses of HIV Infection

Diagnoses of HIV infection are the numbers of persons aged  $\geq 13$  years with HIV diagnosed during 2017–2022 (Tables 3a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2016–2020 diagnoses) found that, on average, approximately 80% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 98% of HIV diagnoses are reported to CDC by the end of the following year. Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting diagnoses of HIV infection can be found in the *HIV Surveillance Report, 2021* at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>.

## Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged  $\geq 13$  years whose infection was diagnosed during January 2021 through September 2022 and who resided in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC at the time of diagnosis (Tables 4a–c). The numerator is the number of persons aged  $\geq 13$  years whose HIV infection was diagnosed during January 2021 through September 2022 and who had  $\geq 1$  CD4 or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged  $\geq 13$  years whose HIV infection was diagnosed during January 2021 through September 2022. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2021 through September 2022 and reported to NHSS through December 2022. Data are not provided for states and associated areas that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia County), and Puerto Rico.

More information on calculating linkage to care can be found in the report *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021* at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>.

## HIV Viral Suppression

Viral suppression at most recent test during 2021 is measured for persons aged  $\geq 13$  years who resided, as of their most recent known address during 2021, in any of the jurisdictions (including EHE Phase I jurisdictions) with complete reporting of laboratory data to CDC and who were alive at the end of 2021 (Tables 5a–c). The numerator is the number of persons aged  $\geq 13$  years with HIV infection diagnosed by the end of 2020 and who had a VL of  $< 200$  copies/mL at the most recent test in 2021. The denominator is the number of persons aged  $\geq 13$  years with HIV diagnosed by the end of 2020 and who were alive at the end of 2021. Data used to calculate prevalence are based on deaths reported to CDC as of December 2022. The following areas had incomplete reporting of deaths for the year 2021, and viral suppression data should be interpreted with caution: Mississippi. Data are not provided for states and associated areas that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia County), and Puerto Rico.

More information on calculating viral suppression can be found in the report *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021* at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>.

## Preexposure Prophylaxis (PrEP) Coverage

PrEP coverage, reported as a percentage, is defined as the number of persons aged  $\geq 16$  years classified as having been prescribed PrEP during the specified year divided by the estimated number of persons aged  $\geq 16$  years who had indications for PrEP during the specified year (Tables 6a–c). PrEP coverage is an EHE indicator that is not a reportable disease or condition and is not reported to NHSS. Multiple data sources, described below, are used to calculate PrEP coverage.

Please use caution when interpreting PrEP data. Different data sources were used in the numerator and denominator to calculate PrEP coverage.

## Persons prescribed PrEP

National pharmacy data from the IQVIA Real World Data—Longitudinal Prescriptions database (hereafter, IQVIA database) are used to classify persons aged  $\geq 16$  years who have been prescribed PrEP in the specific year. The IQVIA database captures prescriptions from all payers and represents approximately 93% of all prescriptions from retail pharmacies and 77% from mail-order outlets in the United States. The database does not include prescriptions from some closed health care systems that do not make their prescription data available to IQVIA. Therefore, these are minimum estimates of PrEP coverage. The annual number of persons classified as having been prescribed PrEP was based on a validated algorithm that discerns whether tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was prescribed for PrEP after excluding prescriptions for HIV treatment, hepatitis B treatment, or HIV postexposure prophylaxis [10–12]. Tenofovir alafenamide and emtricitabine (TAF/FTC) was approved as an alternative drug for PrEP by the U.S. Food and Drug Administration (FDA) in October 2019. Long-acting injectable cabotegravir (CAB-LA) was approved by the FDA as an additional prevention option for PrEP in December 2021. TAF/FTC and injectable cabotegravir were included in the algorithm after their approval to classify the number of persons prescribed PrEP.

The number of persons classified as having been prescribed PrEP is reported by sex, age group, and race/ethnicity. Transmission category data are not available in the IQVIA database, and race/ethnicity data are available for  $< 40\%$  of persons with PrEP prescriptions. Please use caution when interpreting PrEP data by race/ethnicity. Race/ethnicity categories available in the IQVIA database include White, Black/African American, Hispanic/Latino, and other. The number of persons prescribed PrEP for each racial/ethnic group presented in this report was extrapolated by applying the racial/ethnic distribution of known records to those for which data on race/ethnicity were unknown.

## Geographic Designations

In the IQVIA database, a person's location is reported as a 3-digit ZIP code prefix (hereafter, ZIP3) assigned by the U.S. Postal Service. To estimate the number of persons prescribed PrEP at the state or county level, a probability-based approach is used to crosswalk between ZIP3s and states/counties by using data from (a) the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates by ZIP Code Tabulation Areas (ZCTAs) [13], and (b) the U.S. Department of Housing and Urban Development's ZIP Code Crosswalk Files [14]. Because of reliability concerns, subnational estimates of  $< 40$  are not included.

## Persons with PrEP indications

U.S. Census Bureau files and their ACS were used to estimate the number of men who have sex with men (MSM) in a jurisdiction [15, 16]. Next, behavioral data from the National Health and Nutrition Examination Survey (NHANES) were used to estimate the proportion of HIV-negative MSM with indications for PrEP [17].

The number of HIV-negative MSM with indications for PrEP was multiplied by the ratio of percentage of diagnoses during the specified year attributed to other major transmission risk groups compared to the percentage among MSM in a given state or county. The estimated numbers of persons with indications for PrEP in the 3 major transmission risk groups (MSM, heterosexuals, persons who inject drugs) in each jurisdiction were then summed to yield a state- or county-specific estimate. State estimates were then summed for a national total of persons with indications for PrEP [15]. Jurisdictional estimates were rounded to the nearest 10.




The tables included in this report provide updated data on PrEP coverage for the years January 2017–September 2022 by using the IQVIA data reported through September 2022. IQVIA conducts data quality assurance activities. As a result, the number of persons classified as having been prescribed PrEP in a given year might change from time to time. The impact of the changes may vary by demographic category nationally and by jurisdiction. The data sources used to estimate the

number of persons with indications for PrEP have different schedules of availability. Consequently, the availability of a denominator lags the availability of a numerator. PrEP coverage data with a lagged denominator are considered preliminary.

For this release of HIV Surveillance Data Tables, 2018 denominators were used for 2019, 2020, 2021, and 2022 PrEP coverage data; consequently, 2019 through September 2022 PrEP coverage data are considered preliminary. In addition to being preliminary, data for the year 2020 should be interpreted with awareness of the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions [18].

More information on calculating PrEP coverage can be found in the report *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021* at <https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>

## References

1. HHS. What is *Ending the HIV Epidemic in the U.S.*? <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>  . Updated July 2, 2022. Accessed March 13, 2023.
2. CDC [Schuchat A, CDC COVID-19 Response Team]. Public health response to the initiation and spread of pandemic COVID-19 in the United States, February 24–April 21, 2020. *MMWR* 2020;69(18):551–556. doi:<http://dx.doi.org/10.15585/mmwr.mm6918e2>
3. Delaney KP, Jayanthi P, Emerson B, et al. Impact of COVID-19 on commercial laboratory testing for HIV in the United States. 2021 CROI, March 6–10, 2021. Abstract 739.
4. Moitra E, Tao J, Olsen J, et al. Impact of the COVID-19 pandemic on HIV testing rates across four geographically diverse urban centres in the United States: an observational study. *Lancet Reg Health Am* 2022;7:100159. doi:[10.1016/j.lana.2021.100159](https://doi.org/10.1016/j.lana.2021.100159)
5. Chang JJ, Chen Q, Hechter RC, Dionne-Odom J, Bruxvoort K. Changes in HIV and STI testing and diagnoses during the COVID-19 pandemic. 2022 CROI, February 12–16 and 22–24, 2022. Oral Abstract 142.
6. DiNenno EA, Delaney KP, Pitasi MA, et al. HIV testing before and during the COVID-19 pandemic—United States, 2019–2020. *MMWR* 2022;71(25):820–824. doi:[10.15585/mmwr.mm7125a2](https://doi.org/10.15585/mmwr.mm7125a2). PMID: 35737573
7. Song R, Hall HI, Green TA, Szwarcwald CL, Pantazis N. Using CD4 data to estimate HIV incidence, prevalence, and percent of undiagnosed infections in the United States. *J Acquir Immune Defic Syndr* 2017;74(1):3–9. doi:[10.1097/QAI.0000000000001151](https://doi.org/10.1097/QAI.0000000000001151)
8. CDC. *HIV Surveillance Report, 2020*; vol. 33. <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published May 2022. Accessed March 13, 2023.
9. Viguierie A, Song R, Johnson AS, Lyles CM, Hernandez A, Farnham PG. Isolating the effect of COVID-19–related disruptions on HIV diagnoses in the United States in 2020. *J Acquir Immune Defic Syndr* 2023;92(4):293–299. doi:[10.1097/QAI.0000000000003140](https://doi.org/10.1097/QAI.0000000000003140)
10. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. *Clin Infect Dis* 2017;64(2):144–149. doi:[10.1093/cid/ciw701](https://doi.org/10.1093/cid/ciw701)
11. CDC [Huang YA, Zhu W, Smith DK, Harris N, Hoover KW]. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. *MMWR* 2018;67(41):1147–1150. doi:[10.15585/mmwr.mm6741a3](https://doi.org/10.15585/mmwr.mm6741a3)
12. Furukawa NW, Smith DK, Gonzalez CJ, et al. Evaluation of algorithms used for PrEP surveillance using a reference population from New York City, July 2016–June 2018. *Public Health Rep* 2020;135(2):202–210. doi:[10.1177/0033354920904085](https://doi.org/10.1177/0033354920904085)
13. U.S. Census Bureau. American Community Survey 5-year data (2009–2021). <https://www.census.gov/data/developers/data-sets/acs-5year.2019.html>  . Published December 2022. Accessed March 13, 2023.
14. U.S. Department of Housing and Urban Development (HUD). HUD USPS ZIP code crosswalk files. [https://www.huduser.gov/portal/datasets/usps\\_crosswalk.html](https://www.huduser.gov/portal/datasets/usps_crosswalk.html)  . Updated August 2022. Accessed March 13, 2023.
15. Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the population sizes of men who have sex with men in US states and counties using data from the American Community Survey. *JMIR Public Health Surveill* 2016;2(1):e14. doi:[10.2196/publichealth.5365](https://doi.org/10.2196/publichealth.5365)
16. Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. *Open AIDS J* 2012;6:98–107. doi:[10.2174/1874613601206010098](https://doi.org/10.2174/1874613601206010098)

17. CDC [Smith DK, Van Handel M, Wolitski RJ, et al]. Vital Signs: Estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015. *MMWR* 2015;64(46):1291–1295. doi:10.15585/mmwr.mm6446a4
18. Huang YA, Zhu W, Wiener J, Kourtis AP, Hall HI, Hoover KW. Impact of COVID-19 on HIV preexposure prophylaxis prescriptions in the United States—a time series analysis. *Clin Infect Dis* 2022:ciac038. doi:10.1093/cid/ciac038

## Suggested Citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative: National HIV Surveillance System data reported through December 2022; and preexposure prophylaxis (PrEP) data reported through September 2022. *HIV Surveillance Data Tables* 2022;3(4). <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/>. Published May 2023. Accessed [date].

## Confidential information, referrals, and educational material on HIV

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://www.cdc.gov/dcs/ContactUs/Form>

## Acknowledgments

This issue of *HIV Surveillance Data Tables* was prepared by the following staff and contractors of the Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC: Anna Satcher Johnson, Zanetta Gant, Ya-lin Huang, Weiming Zhu, Ruiguang Song, Baohua Wu, Sue Reynolds, Jianmin Li, Xiaohong Hu, Pei Hou, Emily Zhu, Lei Yu, Avery Smithson, Wei Wei, Iddrisu Abdallah, Juliet Morales, Anna Baker, Andre Dailey, Shacara Johnson Lyons, Alex Viguerie, Norma Harris, Stacy Cohen, and Michael Friend (editing and desktop publishing).

The Web and Consumer Services Team of the Prevention Communications Branch are acknowledged for their contributions to the report website.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

**Table 1a. Estimated HIV incidence among persons aged  $\geq 13$  years, by selected characteristics, 2017–2021—United States**

	2017			2018			2019			2020 (COVID-19 pandemic) <sup>a</sup>			2021 <sup>a</sup>		
	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI
<b>Sex at birth</b>															
Male	29,700	2.1	28,500–30,900	29,400	2.4	28,000–30,800	28,500	2.8	26,900–30,000	27,700	3.4	25,900–29,600	25,900	4.0	23,900–27,900
Female	6,800	4.1	6,200–7,300	6,700	4.7	6,100–7,300	6,400	5.4	5,700–7,000	5,900	6.6	5,100–6,700	6,200	6.9	5,400–7,000
<b>Age at infection (yr)</b>															
13–24	9,300	3.7	8,600–10,000	8,400	4.4	7,700–9,200	7,700	5.4	6,900–8,500	6,900	6.8	6,000–7,800	6,100	8.0	5,200–7,100
25–34	13,600	3.1	12,700–14,400	13,800	3.5	12,900–14,800	13,500	4.0	12,500–14,600	13,700	4.8	12,400–14,900	12,600	5.6	11,200–14,000
35–44	6,500	4.5	5,900–7,000	6,700	5.0	6,000–7,300	6,800	5.7	6,000–7,500	6,700	6.9	5,800–7,600	6,800	7.6	5,800–7,800
45–54	4,300	5.5	3,900–4,800	4,200	6.4	3,700–4,800	3,900	7.5	3,400–4,500	3,700	9.2	3,000–4,400	3,600	10.3	2,900–4,300

	2017			2018			2019			2020 (COVID-19 pandemic) <sup>a</sup>			2021 <sup>a</sup>		
	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI
≥55	2,800	7.0	2,400–3,200	2,900	7.6	2,500–3,400	2,900	8.7	2,400–3,400	2,700	10.6	2,200–3,300	3,000	11.3	2,300–3,600
<b>Race/ethnicity</b>															
American Indian/Alaska Native	190	26.3	90–290	180	*31.2	70–280	210	*32.7	70–340	230	*35.9	70–390	190	*45.8	20–360
Asian	600	15.3	420–780	560	18.2	360–760	540	20.3	330–760	510	25.2	260–760	470	29.6	200–750
Black/African American	15,100	2.9	14,300–16,000	15,000	3.3	14,000–15,900	14,400	3.8	13,300–15,400	13,900	4.7	12,600–15,200	13,000	5.4	11,600–14,300
Hispanic/Latino <sup>b</sup>	10,100	3.8	9,400–10,900	10,100	4.3	9,200–10,900	9,600	5.1	8,600–10,600	9,100	6.3	8,000–10,200	9,300	6.9	8,100–10,600
Native Hawaiian/other Pacific Islander	60	*49.1	0–110	...	...	...	...	...	...	...	...	...	...	...	...
White	9,000	3.7	8,400–9,700	9,000	4.2	8,200–9,700	8,800	4.8	8,000–9,600	8,800	5.6	7,800–9,700	8,200	6.5	7,100–9,200
Multiracial	1,400	10.1	1,100–1,600	1,300	11.6	1,000–1,600	1,300	13.3	930–1,600	1,100	17.0	730–1,500	890	21.1	520–1,300
<b>Transmission category<sup>c</sup></b>															
Male-to-male sexual contact <sup>d</sup>	24,500	2.3	23,400–25,600	23,900	2.7	22,700–25,200	23,100	3.1	21,700–24,500	22,700	3.8	21,000–24,400	21,100	4.4	19,300–23,000
Injection drug use <sup>e</sup>	2,400	6.6	2,100–2,700	2,600	7.6	2,200–3,000	2,600	8.6	2,200–3,000	2,600	10.9	2,000–3,100	2,500	12.4	1,900–3,100
Male	1,300	9.7	1,100–1,600	1,500	10.3	1,200–1,800	1,400	12.4	1,100–1,800	1,500	14.7	1,100–2,000	1,400	17.6	930–1,900
Female	1,100	8.9	930–1,300	1,100	10.6	910–1,400	1,200	11.6	890–1,400	1,000	15.6	700–1,300	1,100	17.3	710–1,400
Male-to-male sexual contact <sup>d</sup> and injection drug use <sup>e</sup>	1,400	8.8	1,200–1,600	1,500	9.2	1,200–1,800	1,500	10.4	1,200–1,800	1,400	13.2	1,000–1,700	1,300	15.2	890–1,600
Heterosexual contact <sup>f</sup>	8,100	4.2	7,400–8,800	8,000	4.8	7,200–8,800	7,600	5.5	6,800–8,400	6,900	6.8	6,000–7,800	7,100	7.2	6,100–8,100
Male	2,500	9.1	2,100–3,000	2,500	10.3	2,000–3,000	2,400	11.5	1,900–3,000	2,100	15.1	1,400–2,700	2,000	16.5	1,400–2,700
Female	5,600	4.7	5,100–6,100	5,500	5.3	5,000–6,100	5,200	6.1	4,600–5,800	4,900	7.4	4,200–5,600	5,100	7.6	4,300–5,800
<b>Region of residence</b>															
Northeast	5,100	5.1	4,600–5,600	5,000	5.8	4,400–5,500	4,700	6.9	4,100–5,300	4,600	8.4	3,800–5,300	4,400	9.4	3,600–5,200
Midwest	4,900	5.1	4,400–5,300	4,800	5.8	4,300–5,300	4,500	6.9	3,900–5,200	4,700	8.1	3,900–5,400	4,400	9.2	3,600–5,200
South	19,000	2.6	18,000–20,000	18,800	3.0	17,700–19,900	18,400	3.5	17,100–19,600	17,200	4.3	15,700–18,600	16,700	4.8	15,100–18,200
West	7,500	4.2	6,900–8,100	7,600	4.7	6,900–8,300	7,200	5.5	6,500–8,000	7,200	6.6	6,300–8,200	6,600	7.7	5,600–7,600
<b>Total<sup>g</sup></b>	<b>36,500</b>	<b>1.9</b>	<b>35,100–37,800</b>	<b>36,100</b>	<b>2.2</b>	<b>34,600–37,700</b>	<b>34,800</b>	<b>2.5</b>	<b>33,100–36,600</b>	<b>33,600</b>	<b>3.1</b>	<b>31,600–35,700</b>	<b>32,100</b>	<b>3.5</b>	<b>29,900–34,300</b>

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged  $\geq 13$  years at diagnosis.

Estimates rounded to the nearest 100 for estimates  $> 1,000$  and to the nearest 10 for estimates  $\leq 1,000$  to reflect model uncertainty.

Estimates with an RSE 30%–50%, preceded by an asterisk(\*), should be used with caution.

Estimates with an RSE  $> 50\%$  are not shown and are replaced with an ellipsis (...).

<sup>a</sup> Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of Estimated HIV Incidence and Prevalence in the United States, 2017–2021 for more information.

<sup>b</sup> Hispanic/Latino persons can be of any race.

<sup>c</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

<sup>d</sup> Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>e</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>f</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>g</sup> Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

**Table 1b. Estimated HIV incidence among persons aged  $\geq 13$  years, by area of residence, 2017–2021—United States and Puerto Rico**

Area of residence	2017			2018			2019			2020 (COVID-19 pandemic) <sup>a</sup>			2021 <sup>a</sup>		
	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI
Alabama	620	13.9	450–790	570	16.7	390–760	540	19.9	330–750	590	21.3	340–830	670	22.3	380–970
Alaska	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Arizona	800	13.0	590–1,000	820	14.9	580–1,100	760	18.1	490–1,000	720	22.9	390–1,000	780	24.0	410–1,200
Arkansas	300	23.7	160–430	260	29.6	110–410	330	28.5	150–510	360	*32.2	130–580	380	*33.4	130–640
California	4,600	5.2	4,200–5,100	4,700	5.9	4,100–5,200	4,300	7.1	3,700–4,900	4,300	8.3	3,600–5,000	4,000	9.8	3,200–4,700
Colorado	440	17.1	290–580	400	21.0	230–560	460	21.9	260–650	370	*30.3	150–590	490	28.6	210–760
Connecticut	250	22.5	140–350	210	28.6	90–320	160	*37.9	40–290	200	*40.4	40–360	180	*44.4	20–330
Delaware	120	*33.1	40–200	90	*48.7	0–170	...	...	...	...	...	...	...	...	...
District of Columbia	230	24.8	120–340	230	26.7	110–350	190	*33.5	70–320	140	*47.9	10–280	150	*46.8	10–300
Florida	4,400	5.3	3,900–4,800	4,100	6.3	3,600–4,700	3,900	7.4	3,400–4,500	3,800	9.0	3,100–4,500	3,700	9.9	3,000–4,400
Georgia	2,600	7.4	2,200–3,000	2,500	8.7	2,100–3,000	2,400	10.3	1,900–2,900	2,300	12.9	1,700–2,900	2,300	14.1	1,700–2,900
Hawaii	80	*41.5	10–150	...	...	...	...	...	...	...	...	...	...	...	...
Idaho <sup>b</sup>	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Illinois	1,300	9.8	1,000–1,500	1,300	11.1	1,000–1,600	1,200	13.6	850–1,500	1,100	16.5	780–1,500	1,100	18.8	680–1,500
Indiana	510	16.0	350–670	550	17.4	360–740	500	21.5	290–710	630	22.4	350–900	540	26.4	260–810
Iowa	100	*36.8	30–180	120	*37.7	30–210	140	*39.2	30–250	...	...	...	...	...	...
Kansas	90	*43.0	10–170	120	*40.8	20–210	190	*33.4	60–310	160	*43.7	20–300	...	...	...
Kentucky	330	19.9	200–460	440	18.9	270–600	380	24.3	200–560	390	29.3	170–620	420	*31.7	160–680
Louisiana	920	12.0	700–1,100	950	13.3	700–1,200	840	16.8	560–1,100	880	19.6	540–1,200	760	23.1	420–1,100
Maine	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Maryland	770	13.4	570–970	840	13.8	610–1,100	730	16.9	490–970	680	20.3	410–940	630	23.3	340–910
Massachusetts	500	15.1	350–650	590	15.0	420–760	460	19.8	280–640	350	26.6	170–530	370	28.6	160–570
Michigan	660	13.7	480–840	640	15.7	440–840	600	18.7	380–820	630	21.6	360–890	590	24.7	310–880
Minnesota	250	22.6	140–360	310	22.7	170–450	270	27.8	120–420	240	*34.9	80–410	230	*39.9	50–420

Area of residence	2017			2018			2019			2020 (COVID-19 pandemic) <sup>a</sup>			2021 <sup>a</sup>		
	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI
Mississippi	420	18.6	270–580	440	21.2	260–630	470	23.9	250–690	460	28.9	200–720	420	*36.4	120–730
Missouri	540	13.4	400–690	480	16.8	320–640	460	19.2	290–630	440	24.6	230–660	470	24.2	250–700
Montana	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Nebraska	110	*35.2	30–180	...	...	...	...	...	...	...	...	...	...	...	...
Nevada	530	16.1	370–700	590	17.7	380–790	590	21.0	350–830	610	25.3	300–910	520	*31.3	200–840
New Hampshire	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
New Jersey <sup>b</sup>	1,100	12.2	820–1,300	920	15.2	650–1,200	1,000	16.0	680–1,300	970	20.3	580–1,400	1,100	18.9	670–1,500
New Mexico	140	26.3	70–210	190	25.6	90–280	160	*32.1	60–270	140	*43.0	20–260	130	*48.8	10–260
New York	2,200	7.6	1,900–2,600	2,000	9.1	1,700–2,400	1,900	10.6	1,500–2,300	1,900	12.4	1,400–2,400	1,700	14.5	1,200–2,200
North Carolina	1,300	9.5	1,000–1,500	1,200	11.0	970–1,500	1,400	11.5	1,100–1,700	1,200	15.5	800–1,500	1,100	17.3	700–1,400
North Dakota	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Ohio	920	11.7	710–1,100	890	13.6	660–1,100	860	15.8	590–1,100	810	18.7	510–1,100	850	20.8	500–1,200
Oklahoma	340	18.9	220–470	340	22.3	190–480	430	21.9	250–620	390	28.4	170–610	370	*33.5	130–610
Oregon	190	26.1	90–290	170	*31.4	70–280	190	*33.2	70–320	210	*38.8	50–370	230	*42.6	40–420
Pennsylvania <sup>b</sup>	980	12.9	740–1,200	1,000	13.3	760–1,300	860	15.8	600–1,100	850	18.8	540–1,200	650	23.8	350–950
Puerto Rico <sup>b</sup>	410	18.6	260–560	350	22.4	200–510	320	26.7	150–490	280	*33.6	100–470	280	*35.4	90–470
Rhode Island	80	*34.5	30–140	60	*47.7	0–120	...	...	...	...	...	...	...	...	...
South Carolina	690	15.0	480–890	700	17.2	460–930	670	20.2	400–930	630	23.7	340–920	650	27.5	300–1,000
South Dakota	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Tennessee	750	12.0	570–930	740	13.8	540–940	800	14.5	570–1,000	700	19.1	440–960	720	20.2	430–1,000
Texas	4,400	5.5	3,900–4,800	4,500	6.2	3,900–5,000	4,500	7.0	3,900–5,100	4,200	8.8	3,500–5,000	4,000	10.0	3,300–4,800
Utah	130	*34.1	40–220	140	*37.1	40–240	140	*42.0	30–260	...	...	...	...	...	...
Vermont	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
Virginia	850	12.8	630–1,100	820	14.9	580–1,100	800	17.1	530–1,100	720	21.3	420–1,000	640	24.4	330–950
Washington	450	17.1	300–600	540	17.5	360–730	510	21.0	300–720	450	27.2	210–690	470	*30.2	190–750
West Virginia	110	*37.7	30–200	170	*35.4	50–300	260	*34.1	90–430	...	...	...	...	...	...
Wisconsin	250	23.1	130–360	210	29.5	90–330	220	*33.1	80–360	300	*31.9	110–490	230	*41.5	40–430
Wyoming	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged  $\geq 13$  years at diagnosis.


Estimates rounded to the nearest 100 for estimates  $> 1,000$  and to the nearest 10 for estimates  $\leq 1,000$  to reflect model uncertainty.

Estimates with an RSE 30%–50%, preceded by an asterisk(\*), should be used with caution.

Estimates with an RSE  $> 50\%$  are not shown and are replaced with an ellipsis (...).

<sup>a</sup> Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of Estimated HIV Incidence and Prevalence in the United States, 2017–2021 for more information.

<sup>b</sup> Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

Table 1c. Estimated HIV incidence among persons aged  $\geq 13$  years, by area of residence, 2017–2021—Ending the HIV Epidemic Phase I jurisdictions 

Area of residence	2017			2018			2019			2020 (COVID-19 pandemic) <sup>a</sup>			2021 <sup>a</sup>		
	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI
<b>Arizona</b>															
Maricopa County	570	15.7	390–740	550	18.5	350–750	510	22.2	290–730	470	28.9	200–740	460	*31.9	170–750
<b>California</b>															
Alameda County	190	25.7	90–280	190	28.5	80–300	200	*31.9	80–330	150	*42.5	30–280	170	*45.5	20–320
Los Angeles County	1,500	9.0	1,200–1,800	1,500	10.3	1,200–1,800	1,400	12.1	1,100–1,700	1,400	14.2	980–1,700	1,200	17.1	790–1,600
Orange County	290	20.5	170–410	280	23.6	150–410	230	29.8	90–360	280	*31.5	110–450	230	*38.7	60–410
Riverside County	270	21.5	150–380	290	23.4	150–420	260	27.8	120–410	280	*31.3	110–450	240	*37.9	60–430
Sacramento County	220	23.6	120–320	220	26.8	100–330	210	*31.4	80–330	180	*39.2	40–320	...	...	...
San Bernardino County	270	21.1	160–390	260	24.5	140–390	310	25.5	160–470	310	29.8	130–490	280	*35.5	80–470
San Diego County	430	16.8	290–580	420	19.1	270–580	420	22.1	240–600	370	27.2	170–570	410	29.3	170–640
San Francisco County	170	26.8	80–260	160	*31.5	60–260	120	*41.7	20–210	120	*47.0	10–240	140	*49.9	0–280
<b>District of Columbia</b>	230	24.8	120–340	230	26.7	110–350	190	*33.5	70–320	140	*47.9	10–280	150	*46.8	10–300
<b>Florida</b>															
Broward County	650	13.4	480–820	530	17.1	350–700	540	19.0	340–750	510	23.7	270–740	500	26.2	240–760
Duval County	270	20.8	160–380	240	25.0	120–370	220	*30.1	90–350	280	*32.0	100–450	230	*38.9	50–400
Hillsborough County	300	19.8	180–410	270	23.8	140–400	240	28.7	100–370	290	*31.3	110–470	180	*44.2	20–330
Miami-Dade County	1,100	10.1	910–1,400	1,100	12.1	800–1,300	980	14.2	700–1,200	850	18.3	550–1,200	870	19.8	530–1,200
Orange County	430	16.5	290–560	410	19.5	250–560	450	20.9	270–640	440	25.5	220–670	460	27.4	210–700
Palm Beach County	260	21.2	150–360	260	24.5	130–380	240	28.7	100–370	300	*30.8	120–480	230	*38.3	60–410
Pinellas County	160	26.6	80–250	140	*33.4	50–230	150	*36.6	40–250	160	*42.3	30–290	...	...	...
<b>Georgia</b>															
Cobb County	190	26.1	90–280	160	*33.0	60–260	190	*34.7	60–320	170	*45.1	20–330	...	...	...
DeKalb County	360	18.8	230–490	390	20.9	230–560	320	26.7	150–490	290	*34.5	100–490	320	*37.1	90–550
Fulton County	590	14.7	420–760	620	16.8	410–820	530	21.0	310–750	590	24.5	300–870	530	28.7	230–830
Gwinnett County	160	27.9	70–250	150	*34.3	50–250	190	*34.4	60–330	...	...	...	...	...	...
<b>Illinois</b>															
Cook County	910	11.3	710–1,100	890	13.1	660–1,100	810	15.9	560–1,100	830	18.8	520–1,100	780	21.4	450–1,100
<b>Indiana</b>															
Marion County	220	22.2	130–320	220	25.0	110–330	230	28.5	100–360	240	*33.4	80–400	210	*39.7	50–370
<b>Louisiana</b>															
East Baton Rouge Parish	170	26.3	80–250	180	28.5	80–280	160	*34.2	50–280	120	*49.2	0–240	...	...	...

Area of residence	2017			2018			2019			2020 (COVID-19 pandemic) <sup>a</sup>			2021 <sup>a</sup>		
	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI
Orleans Parish	150	27.9	70-230	150	*30.6	60-240	130	*38.4	30-230	...	...	...	...	...	...
<b>Maryland</b>															
Baltimore City	200	26.9	90-300	210	27.2	100-330	130	*40.4	30-240	180	*40.4	40-310	150	*48.0	10-280
Montgomery County	100	*37.8	30-170	90	*41.1	20-170	100	*47.6	10-180	...	...	...	...	...	...-...
Prince George's County	200	26.3	100-310	260	24.8	130-380	230	*30.3	90-370	170	*41.6	30-300	200	*41.1	40-360
<b>Massachusetts</b>															
Suffolk County	120	26.0	60-180	120	27.5	60-190	120	*31.1	50-190	120	*33.9	40-200	120	*38.7	30-210
<b>Michigan</b>															
Wayne County	280	20.1	170-390	270	23.8	140-390	280	25.8	140-420	270	*31.1	110-440	220	*39.7	50-390
<b>Nevada</b>															
Clark County	480	16.3	330-630	520	18.3	330-700	490	22.4	270-700	530	25.7	260-800	460	*32.2	170-740
<b>New Jersey</b>															
Essex County <sup>b</sup>	310	21.4	180-440	220	29.9	90-340	200	*35.9	60-330	230	*38.6	60-400	270	*34.3	90-450
Hudson County <sup>b</sup>	160	29.7	70-250	150	*35.7	50-260	110	*48.0	10-210	140	*48.7	10-280	130	*49.0	0-260
<b>New York</b>															
Bronx County	400	17.2	270-540	390	19.4	240-540	370	23.1	200-540	390	26.0	190-580	380	29.1	160-600
Kings County	470	15.8	330-620	450	18.4	290-610	400	22.2	230-580	380	26.2	180-570	360	*30.0	150-570
New York County	350	18.4	220-470	310	22.1	170-440	270	26.8	130-420	300	29.4	130-470	260	*35.1	80-440
Queens County	330	18.7	210-460	320	21.5	190-460	250	28.2	110-390	290	*30.0	120-460	270	*34.7	80-450
<b>North Carolina</b>															
Mecklenburg County	290	18.7	180-390	240	23.6	130-350	290	23.2	160-420	250	*31.2	100-400	190	*37.9	50-330
<b>Ohio</b>															
Cuyahoga County	130	*30.4	50-210	130	*33.7	40-220	130	*38.9	30-230	160	*38.6	40-290	160	*46.8	10-300
Franklin County	190	25.0	100-280	200	27.5	90-310	210	*30.7	80-330	180	*37.1	50-310	150	*47.3	10-300
Hamilton County	150	27.9	70-230	140	*32.9	50-230	130	*39.3	30-220	120	*44.7	10-230	...	...	...
<b>Pennsylvania</b>															
Philadelphia County	390	16.1	270-520	410	17.4	270-550	410	19.4	250-560	280	*30.7	110-440	290	*31.3	110-470
<b>Puerto Rico</b>															
San Juan Municipio <sup>b</sup>	100	*35.2	30-170	70	*48.4	0-130	80	*47.1	10-150	...	...	...	...	...	...
<b>Tennessee</b>															
Shelby County	240	20.0	150-340	250	21.9	140-360	280	23.3	150-400	210	*32.6	80-350	220	*33.6	80-370
<b>Texas</b>															
Bexar County	300	20.2	180-420	320	22.5	180-460	370	23.9	200-540	380	28.5	170-600	310	*35.2	90-520
Dallas County	830	12.3	630-1,000	820	14.1	600-1,100	650	17.9	420-880	730	20.5	440-1,000	750	22.5	420-1,100
Harris County	1,100	10.4	910-1,400	1,100	12.0	860-1,400	1,200	13.5	850-1,500	1,100	16.9	730-1,400	1,000	19.0	660-1,400
Tarrant County	300	20.6	180-420	280	23.8	150-420	380	23.5	210-560	29.2	150	570-320	320	*34.6	100-530
Travis County	210	24.7	110-310	240	26.0	120-360	180	*34.4	60-300	*42.7	30	310-190	190	*45.1	20-350

Area of residence	2017			2018			2019			2020 (COVID-19 pandemic) <sup>a</sup>			2021 <sup>a</sup>		
	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI	No.	RSE	95% CI
<b>Washington</b>															
King County	210	25.8	100–310	260	25.0	130–390	220	*33.2	80–360	*39.6	50	370–200	200	*46.3	20–390

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage [footnotes only]; CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Estimates derived by using HIV surveillance data and CD4 data for persons aged  $\geq 13$  years at diagnosis.


Estimates rounded to the nearest 100 for estimates  $> 1,000$  and to the nearest 10 for estimates  $\leq 1,000$  to reflect model uncertainty.

Estimates with an RSE 30%–50%, preceded by an asterisk(\*), should be used with caution.

Estimates with an RSE  $> 50\%$  are not shown and are replaced with an ellipsis (...).

<sup>a</sup> Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of Estimated HIV Incidence and Prevalence in the United States, 2017–2021 for more information.

<sup>b</sup> Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

**Table 2a. Estimated HIV prevalence among persons aged  $\geq 13$  years, by selected characteristics, 2017–2021—United States** 

	2017							2018						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
<b>Sex at birth</b>														
Male	886,200	0.3	880,100–892,200	753,766	85.1	0.4	84.5–85.6	904,500	0.4	898,300–910,800	772,969	85.5	0.4	84.9–86.1
Female	256,600	0.6	253,500–259,600	228,901	89.2	0.6	88.2–90.3	259,800	0.6	256,700–263,000	232,542	89.5	0.6	88.4–90.6
<b>Age (yr)</b>														
13–24	65,200	1.0	63,900–66,500	27,742	42.6	1.0	41.7–43.4	59,200	1.2	57,800–60,600	26,607	45.0	1.2	43.9–46.0
25–34	203,900	0.5	201,900–206,000	148,377	72.8	0.5	72.0–73.5	211,200	0.5	209,000–213,500	153,232	72.5	0.5	71.8–73.3
35–44	216,800	0.4	214,900–218,600	186,686	86.1	0.4	85.4–86.9	220,200	0.5	218,300–222,200	189,167	85.9	0.5	85.1–86.7
45–54	313,600	0.3	311,400–315,700	291,493	93.0	0.3	92.3–93.6	301,000	0.4	298,800–303,100	279,604	92.9	0.4	92.2–93.6
$\geq 55$	343,200	0.4	340,400–346,100	328,369	95.7	0.4	94.9–96.5	372,800	0.4	369,800–375,800	356,901	95.7	0.4	95.0–96.5
<b>Race/ethnicity</b>														
American Indian/Alaska Native	3,500	5.6	3,100–3,900	2,730	77.3	5.6	69.7–86.7	3,700	5.6	3,300–4,100	2,853	77.9	5.7	70.2–87.5
Asian <sup>c</sup>	16,500	2.3	15,800–17,300	13,516	81.8	2.3	78.3–85.7	17,100	2.3	16,300–17,900	14,375	84.1	2.3	80.5–88.1
Black/African American	461,000	0.5	456,700–465,400	395,740	85.8	0.5	85.0–86.7	469,600	0.5	465,100–474,100	404,951	86.2	0.5	85.4–87.1
Hispanic/Latino <sup>d</sup>	268,800	0.6	265,700–272,000	223,165	83.0	0.6	82.0–84.0	277,000	0.6	273,700–280,200	231,101	83.4	0.6	82.5–84.4

	2017							2018						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
Native Hawaiian/other Pacific Islander	990	9.9	800–1,200	739	74.4	10.3	62.3–92.3	1,000	10.1	830–1,200	784	75.8	10.5	63.3–94.4
White	329,600	0.6	325,700–333,400	291,194	88.4	0.6	87.3–89.4	333,600	0.6	329,600–337,500	295,534	88.6	0.6	87.6–89.7
Multiracial	61,600	1.2	60,200–63,000	54,920	89.2	1.2	87.2–91.3	61,800	1.2	60,400–63,300	55,250	89.4	1.2	87.3–91.5
<b>Transmission category<sup>e</sup></b>														
Male-to-male sexual contact <sup>f</sup>	655,100	0.4	650,000–660,200	549,064	83.8	0.4	83.2–84.5	673,000	0.4	667,700–678,200	567,472	84.3	0.4	83.7–85.0
Injection drug use <sup>g</sup>	125,900	1.1	123,300–128,500	116,784	92.8	1.1	90.9–94.7	125,200	1.1	122,500–127,800	115,950	92.6	1.1	90.7–94.6
Male	73,200	1.5	71,100–75,300	67,774	92.6	1.5	90.1–95.3	72,600	1.5	70,500–74,700	67,101	92.4	1.5	89.8–95.2
Female	52,700	1.5	51,200–54,200	49,011	93.0	1.5	90.4–95.8	52,600	1.5	51,000–54,100	48,850	92.9	1.5	90.2–95.8
Male-to-male sexual contact <sup>f</sup> and injection drug use <sup>g</sup>	63,400	1.3	61,800–65,000	58,001	91.5	1.3	89.2–93.9	63,500	1.3	61,900–65,200	58,116	91.5	1.3	89.2–93.9
Heterosexual contact <sup>h</sup>	294,500	0.6	291,200–297,700	255,234	86.7	0.6	85.7–87.7	298,900	0.6	295,500–302,200	260,362	87.1	0.6	86.1–88.1
Male	92,200	1.1	90,300–94,200	76,847	83.3	1.1	81.6–85.1	93,200	1.1	91,200–95,300	78,210	83.9	1.1	82.1–85.8
Female	202,200	0.7	199,600–204,800	178,387	88.2	0.7	87.1–89.4	205,600	0.7	202,900–208,300	182,152	88.6	0.7	87.4–89.8
<b>Region of residence</b>														
Northeast	248,600	0.7	245,300–251,800	226,712	91.2	0.7	90.0–92.4	250,000	0.7	246,700–253,400	228,784	91.5	0.7	90.3–92.7
Midwest	139,100	0.9	136,800–141,500	117,129	84.2	0.9	82.8–85.6	142,000	0.9	139,600–144,400	120,165	84.6	0.9	83.2–86.1
South	527,000	0.4	522,500–531,600	443,937	84.2	0.4	83.5–85.0	538,900	0.4	534,200–543,600	456,294	84.7	0.4	83.9–85.4
West	228,000	0.7	225,000–231,000	194,889	85.5	0.7	84.4–86.6	233,400	0.7	230,300–236,500	200,268	85.8	0.7	84.7–87.0
<b>Total<sup>i</sup></b>	<b>1,142,700</b>	<b>0.3</b>	<b>1,135,900–1,149,500</b>	<b>982,667</b>	<b>86.0</b>	<b>0.3</b>	<b>85.5–86.5</b>	<b>1,164,400</b>	<b>0.3</b>	<b>1,157,400–1,171,400</b>	<b>1,005,511</b>	<b>86.4</b>	<b>0.3</b>	<b>85.8–86.9</b>

	2019							2020 (COVID-19 pandemic) <sup>a</sup>						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
<b>Sex at birth</b>														
Male	921,900	0.4	915,400–928,400	791,399	85.8	0.4	85.2–86.5	932,300	0.4	925,600–939,100	802,910	86.1	0.4	85.5–86.7
Female	262,900	0.6	259,700–266,100	236,166	89.8	0.6	88.7–90.9	263,600	0.6	260,300–267,000	237,346	90.0	0.6	88.9–91.2
<b>Age (yr)</b>														
13–24	53,500	1.4	52,000–55,000	25,934	48.5	1.4	47.2–49.9	46,900	1.7	45,300–48,500	24,027	51.3	1.8	49.6–53.1

	2019							2020 (COVID-19 pandemic) <sup>a</sup>						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
25-34	216,200	0.6	213,800-218,700	156,651	72.4	0.6	71.6-73.3	217,100	0.7	214,300-219,900	156,512	72.1	0.7	71.2-73.0
35-44	225,100	0.5	223,000-227,200	192,529	85.5	0.5	84.7-86.4	230,200	0.5	227,900-232,600	195,916	85.1	0.5	84.2-86.0
45-54	287,400	0.4	285,300-289,600	266,664	92.8	0.4	92.1-93.5	273,800	0.4	271,600-276,000	253,579	92.6	0.4	91.9-93.4
≥ 55	402,600	0.4	399,500-405,700	385,787	95.8	0.4	95.1-96.6	428,000	0.4	424,700-431,200	410,222	95.9	0.4	95.1-96.6
<b>Race/ethnicity</b>														
American Indian/Alaska Native	3,800	5.7	3,400-4,200	2,990	78.4	5.8	70.6-88.2	3,900	5.9	3,500-4,400	3,099	78.8	6.0	70.6-89.1
Asian <sup>c</sup>	17,700	2.3	16,900-18,500	15,118	85.6	2.3	81.9-89.7	18,100	2.4	17,200-18,900	15,721	87.1	2.4	83.2-91.3
Black/African American	477,600	0.5	473,000-482,200	413,920	86.7	0.5	85.8-87.5	481,700	0.5	476,900-486,500	418,714	86.9	0.5	86.1-87.8
Hispanic/Latino <sup>d</sup>	284,700	0.6	281,200-288,100	239,069	84.0	0.6	83.0-85.0	289,500	0.6	285,900-293,200	244,303	84.4	0.6	83.3-85.5
Native Hawaiian/other Pacific Islander	1,100	10.2	850-1,300	830	78.0	10.7	64.9-97.6	1,100	10.7	880-1,300	882	79.8	10.9	66.0-100
White	337,300	0.6	333,300-341,300	299,443	88.8	0.6	87.7-89.8	339,300	0.6	335,100-343,400	301,619	88.9	0.6	87.8-90.0
Multiracial	62,000	1.2	60,600-63,500	55,536	89.5	1.2	87.4-91.7	61,700	1.3	60,200-63,200	55,260	89.6	1.3	87.4-91.8
<b>Transmission category<sup>e</sup></b>														
Male-to-male sexual contact <sup>f</sup>	689,900	0.4	684,500-695,300	585,215	84.8	0.4	84.2-85.5	701,900	0.4	696,200-707,600	598,237	85.2	0.4	84.5-85.9
Injection drug use <sup>g</sup>	124,500	1.1	121,900-127,200	115,253	92.6	1.1	90.6-94.6	123,000	1.1	120,200-125,700	113,525	92.3	1.1	90.3-94.4
Male	72,100	1.5	69,900-74,200	66,494	92.2	1.5	89.6-95.1	71,100	1.6	68,900-73,300	65,327	91.9	1.6	89.1-94.8
Female	52,400	1.5	50,900-54,000	48,759	93.0	1.5	90.2-95.9	51,800	1.6	50,200-53,500	48,198	93.0	1.6	90.1-96.0
Male-to-male sexual contact <sup>f</sup> and injection drug use <sup>g</sup>	63,600	1.3	62,000-65,300	58,324	91.6	1.3	89.3-94.1	63,200	1.4	61,500-64,900	57,858	91.5	1.4	89.1-94.1
Heterosexual contact <sup>h</sup>	302,900	0.6	299,400-306,300	265,124	87.5	0.6	86.5-88.6	304,000	0.6	300,400-307,600	267,001	87.8	0.6	86.8-88.9
Male	94,100	1.1	92,000-96,200	79,292	84.3	1.1	82.4-86.2	93,900	1.2	91,700-96,100	79,440	84.6	1.2	82.6-86.6
Female	208,800	0.7	206,000-211,500	185,832	89.0	0.7	87.8-90.2	210,100	0.7	207,200-212,900	187,561	89.3	0.7	88.1-90.5
<b>Region of residence</b>														
Northeast	250,900	0.7	247,500-254,300	230,293	91.8	0.7	90.6-93.0	250,200	0.7	246,700-253,700	229,844	91.9	0.7	90.6-93.2
Midwest	144,500	0.9	142,000-147,000	122,883	85.0	0.9	83.6-86.5	146,400	0.9	143,800-149,000	124,830	85.3	0.9	83.8-86.8
South	550,900	0.5	546,000-555,800	468,902	85.1	0.5	84.4-85.9	558,000	0.5	552,900-563,100	476,871	85.5	0.5	84.7-86.3
West	238,500	0.7	235,300-241,700	205,487	86.2	0.7	85.0-87.3	241,400	0.7	238,100-244,800	208,711	86.4	0.7	85.3-87.7

	2019							2020 (COVID-19 pandemic) <sup>a</sup>						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
<b>Total<sup>i</sup></b>	1,184,800	0.3	1,177,600–1,192,100	1,027,565	86.7	0.3	86.2–87.3	1,196,000	0.3	1,188,400–1,203,500	1,040,256	87.0	0.3	86.4–87.5

	2021 <sup>a</sup>							
	Persons living with diagnosed or undiagnosed HIV infection				Persons living with diagnosed HIV infection			
	No.	RSE	95% CI		No. <sup>b</sup>	%	RSE	95% CI
<b>Sex at birth</b>								
Male	946,500	0.4	939,400–953,500		819,141	86.5	0.4	85.9–87.2
Female	265,900	0.7	262,500–269,300		239,759	90.2	0.7	89.0–91.3
<b>Age (yr)</b>								
13–24	41,900	2.1	40,200–43,700		23,671	56.4	2.1	54.2–58.9
25–34	217,100	0.7	214,000–220,200		157,035	72.3	0.7	71.3–73.4
35–44	238,300	0.6	235,700–241,000		202,019	84.8	0.6	83.8–85.7
45–54	263,000	0.4	260,700–265,300		243,001	92.4	0.4	91.6–93.2
≥ 55	452,000	0.4	448,600–455,400		433,174	95.8	0.4	95.1–96.6
<b>Race/ethnicity</b>								
American Indian/Alaska Native	4,100	6.1	3,600–4,500		3,245	80.1	6.2	71.5–91.0
Asian <sup>c</sup>	18,600	2.4	17,700–19,400		16,455	88.7	2.5	84.6–93.1
Black/African American	487,500	0.5	482,500–492,500		425,519	87.3	0.5	86.4–88.2
Hispanic/Latino <sup>d</sup>	297,200	0.7	293,400–301,100		252,342	84.9	0.7	83.8–86.0
Native Hawaiian/other Pacific Islander	1,200	11.1	950–1,400		948	80.7	10.6	66.3–100
White	342,000	0.6	337,800–346,300		304,871	89.1	0.6	88.0–90.3
Multiracial	61,200	1.3	59,600–62,800		54,864	89.6	1.3	87.4–92.0
<b>Transmission category<sup>e</sup></b>								
Male-to-male sexual contact <sup>f</sup>	716,900	0.4	710,900–722,900		615,019	85.8	0.4	85.1–86.5
Injection drug use <sup>g</sup>	121,900	1.2	119,200–124,700		112,395	92.2	1.2	90.1–94.3
Male	70,400	1.6	68,100–72,600		64,530	91.7	1.6	88.8–94.7
Female	51,600	1.6	49,900–53,200		47,864	92.8	1.6	89.9–95.9
Male-to-male sexual contact <sup>f</sup> and injection drug use <sup>g</sup>	62,900	1.4	61,100–64,600		57,559	91.6	1.4	89.1–94.2
Heterosexual contact <sup>h</sup>	306,700	0.6	303,000–310,500		270,255	88.1	0.6	87.0–89.2
Male	94,100	1.2	91,800–96,400		79,991	85.0	1.2	82.9–87.1
Female	212,600	0.7	209,600–215,600		190,265	89.5	0.7	88.3–90.8
<b>Region of residence</b>								
Northeast	250,600	0.7	247,100–254,200		230,704	92.0	0.7	90.7–93.4
Midwest	148,800	0.9	146,000–151,500		127,435	85.7	0.9	84.1–87.3
South	567,800	0.5	562,400–573,200		487,976	85.9	0.5	85.1–86.8
West	245,200	0.7	241,700–248,700		212,785	86.8	0.7	85.6–88.0
<b>Total<sup>i</sup></b>	<b>1,212,400</b>	<b>0.3</b>	<b>1,204,500–1,220,200</b>		<b>1,058,900</b>	<b>87.3</b>	<b>0.3</b>	<b>86.8–87.9</b>

Abbreviations: RSE, relative standard error; CI, confidence interval; CDC, the Centers for Disease Control and Prevention [footnotes only]; CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage [footnotes only].

Note. Estimates for the year 2021 data are preliminary and based on deaths reported to CDC as of December 2022. Estimates derived by using HIV surveillance data and CD4 data for persons aged  $\geq$  13 years at diagnosis.

<sup>a</sup> Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of Estimated HIV Incidence and Prevalence in the United States, 2017–2021 for more information.

<sup>b</sup> Reported to the National HIV Surveillance System.

<sup>c</sup> Includes Asian/Pacific Islander legacy cases.

<sup>d</sup> Hispanic/Latino persons can be of any race.

<sup>e</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

<sup>f</sup> Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>g</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>h</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>i</sup> Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

**Table 2b. Estimated HIV prevalence among persons aged  $\geq 13$  years, by area of residence, 2017–2021—United States and Puerto Rico**

	2017							2018						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
Alabama	15,600	2.6	14,800–16,400	12,899	82.5	2.6	78.6–86.9	16,000	2.6	15,200–16,800	13,331	83.2	2.6	79.1–87.6
Alaska	820	10.8	710–1,000	705	85.7	8.7	70.7–100	810	11.2	690–990	694	85.2	9.0	69.8–100
Arizona	18,800	2.2	18,000–19,600	15,606	83.1	2.2	79.6–86.9	19,500	2.2	18,600–20,300	16,246	83.4	2.3	79.9–87.2
Arkansas	6,900	3.8	6,400–7,400	5,458	79.0	3.9	73.5–85.5	7,000	3.9	6,500–7,600	5,614	79.8	4.0	74.1–86.4
California	146,700	0.8	144,300–149,100	126,922	86.5	0.8	85.1–88.0	149,300	0.9	146,800–151,800	129,640	86.8	0.9	85.4–88.3
Colorado	13,800	2.6	13,100–14,500	11,969	86.7	2.6	82.5–91.3	14,300	2.6	13,500–15,000	12,422	87.1	2.6	82.9–91.7
Connecticut	11,200	3.1	10,500–11,900	10,138	90.5	3.1	85.3–96.4	11,300	3.1	10,600–12,000	10,281	91.1	3.2	85.8–97.0
Delaware	3,700	5.3	3,300–4,100	3,218	86.9	5.4	78.7–97.0	3,700	5.4	3,300–4,100	3,240	87.1	5.5	78.7–97.4
District of Columbia	15,100	2.7	14,300–15,900	14,039	93.0	2.7	88.4–98.1	14,900	2.7	14,100–15,700	13,917	93.2	2.7	88.5–98.5
Florida	125,800	0.9	123,600–128,100	107,755	85.6	0.9	84.1–87.2	127,700	0.9	125,400–130,000	109,843	86.0	0.9	84.5–87.6
Georgia	63,600	1.2	62,100–65,100	52,255	82.2	1.2	80.3–84.2	65,600	1.2	64,000–67,200	54,270	82.7	1.2	80.8–84.7
Hawaii	2,700	6.4	2,400–3,000	2,376	88.5	6.2	78.6–100	2,600	6.7	2,300–3,000	2,324	88.8	6.2	78.5–100
Idaho <sup>c</sup>	1,500	10.7	1,200–1,800	1,093	74.2	11.2	61.3–93.9	1,500	11.2	1,200–1,900	1,143	74.4	11.8	61.1–95.4
Illinois	39,800	1.6	38,600–41,100	34,336	86.2	1.6	83.5–89.1	40,500	1.6	39,200–41,900	35,131	86.6	1.7	83.9–89.5
Indiana	13,000	2.7	12,300–13,700	10,859	83.4	2.7	79.1–88.1	13,400	2.8	12,700–14,100	11,209	83.6	2.8	79.3–88.4
Iowa	3,100	5.1	2,800–3,400	2,634	84.4	5.2	76.7–93.9	3,200	5.2	2,900–3,600	2,744	84.7	5.2	76.9–94.3

	2017							2018						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
Kansas	3,600	5.3	3,200–4,000	2,972	82.5	5.4	74.7–92.2	3,600	5.5	3,200–4,000	3,043	83.7	5.6	75.6–93.8
Kentucky	8,400	3.3	7,900–9,000	6,903	81.8	3.3	76.9–87.4	8,700	3.3	8,200–9,300	7,154	81.8	3.3	76.8–87.4
Louisiana	24,100	2.1	23,100–25,100	20,019	83.2	2.1	79.8–86.8	24,500	2.2	23,500–25,600	20,491	83.5	2.2	80.1–87.2
Maine	1,800	7.5	1,500–2,000	1,537	86.5	7.3	75.4–100	1,800	7.6	1,600–2,100	1,585	87.0	7.1	75.7–100
Maryland	36,100	1.7	34,900–37,300	32,102	89.0	1.7	86.1–92.0	36,400	1.7	35,200–37,700	32,609	89.5	1.7	86.6–92.6
Massachusetts	22,000	2.1	21,100–22,900	19,945	90.7	2.1	87.2–94.6	22,200	2.1	21,300–23,100	20,248	91.1	2.1	87.5–95.0
Michigan	18,300	2.5	17,400–19,200	15,449	84.5	2.5	80.6–88.8	18,500	2.5	17,600–19,400	15,762	85.1	2.5	81.1–89.5
Minnesota	9,300	3.0	8,800–9,900	8,140	87.1	3.1	82.2–92.7	9,600	3.0	9,100–10,200	8,416	87.3	3.1	82.4–92.9
Mississippi <sup>d</sup>	11,000	3.1	10,300–11,700	9,089	82.5	3.2	77.7–87.9	11,200	3.2	10,400–11,900	9,259	83.0	3.2	78.1–88.6
Missouri	14,000	2.7	13,300–14,700	12,140	86.7	2.7	82.4–91.5	14,300	2.7	13,600–15,100	12,445	86.7	2.7	82.4–91.5
Montana	680	10.2	600–820	604	88.9	7.4	74.1–100	700	10.2	630–840	628	90.2	7.1	75.1–100
Nebraska	2,500	6.0	2,200–2,800	2,085	83.7	6.1	74.9–95.0	2,500	6.1	2,200–2,800	2,128	84.7	6.2	75.6–96.4
Nevada	11,600	2.8	10,900–12,200	9,397	81.2	2.8	77.0–85.9	12,200	2.8	11,600–12,900	9,975	81.5	2.8	77.3–86.2
New Hampshire	1,300	8.7	1,200–1,500	1,156	88.3	7.1	75.5–100	1,400	8.5	1,200–1,600	1,224	89.1	6.8	76.4–100
New Jersey <sup>c</sup>	38,300	1.9	36,900–39,800	33,765	88.1	1.9	84.9–91.4	38,400	1.9	36,900–39,800	33,888	88.3	1.9	85.1–91.8
New Mexico	3,900	4.6	3,600–4,300	3,382	86.6	4.7	79.4–95.2	4,100	4.5	3,800–4,500	3,579	86.6	4.6	79.5–95.0
New York	133,000	0.9	130,600–135,300	122,472	92.1	0.9	90.5–93.8	133,200	0.9	130,800–135,600	123,159	92.4	0.9	90.8–94.1
North Carolina	35,600	1.6	34,500–36,700	30,380	85.4	1.6	82.8–88.2	36,600	1.6	35,400–37,700	31,306	85.6	1.6	83.0–88.4
North Dakota	630	13.7	460–800	404	64.3	14.8	50.7–88.1	680	13.9	500–870	442	64.8	15.0	50.9–89.2
Ohio	25,700	1.9	24,700–26,700	21,502	83.7	1.9	80.6–87.0	26,200	2.0	25,200–27,200	22,066	84.3	2.0	81.2–87.6
Oklahoma	7,300	3.8	6,800–7,900	5,930	81.1	3.8	75.5–87.6	7,500	3.8	7,000–8,100	6,091	80.9	3.8	75.3–87.4
Oregon	7,700	3.3	7,200–8,200	6,808	88.4	3.4	83.0–94.6	7,800	3.4	7,300–8,300	6,983	89.3	3.4	83.7–95.6
Pennsylvania <sup>c</sup>	38,700	1.6	37,500–39,900	34,533	89.2	1.6	86.5–92.2	39,300	1.7	38,100–40,600	35,164	89.4	1.7	86.6–92.4
Puerto Rico <sup>c,d</sup>	17,500	3.0	16,500–18,500	15,628	89.3	3.0	84.4–94.9	17,300	3.1	16,200–18,300	15,483	89.7	3.1	84.6–95.4
Rhode Island	2,800	5.8	2,500–3,100	2,498	90.0	5.4	80.8–100	2,800	5.8	2,500–3,100	2,549	90.6	5.3	81.3–100
South Carolina	19,600	2.3	18,700–20,500	16,214	82.8	2.3	79.2–86.7	20,000	2.3	19,100–20,900	16,683	83.3	2.3	79.6–87.3

	2017							2018						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
South Dakota	740	12.0	570–910	565	76.8	12.6	62.1–100	770	12.3	600–960	600	77.7	12.3	62.6–100
Tennessee	19,600	2.3	18,700–20,400	16,564	84.7	2.3	81.1–88.6	20,200	2.2	19,300–21,000	17,166	85.2	2.3	81.6–89.1
Texas	106,300	1.0	104,300–108,300	87,340	82.2	1.0	80.6–83.7	109,800	1.0	107,800–111,900	90,838	82.7	1.0	81.2–84.3
Utah	3,300	5.4	3,000–3,700	2,725	82.0	5.5	74.2–91.7	3,500	5.3	3,200–3,900	2,910	82.5	5.4	74.7–92.1
Vermont	730	10.0	670–880	668	91.0	6.7	76.0–100	740	10.1	690–890	686	92.4	6.3	77.2–100
Virginia	25,700	2.0	24,700–26,700	21,991	85.5	2.0	82.2–89.0	26,300	2.0	25,200–27,300	22,597	86.0	2.0	82.7–89.5
Washington	14,900	2.5	14,200–15,600	12,980	87.1	2.5	83.0–91.6	15,400	2.5	14,600–16,100	13,381	87.1	2.5	83.1–91.7
West Virginia	2,200	6.8	1,900–2,500	1,781	79.8	6.9	70.4–92.0	2,400	6.8	2,100–2,700	1,885	77.9	6.9	68.8–89.9
Wisconsin	7,100	3.7	6,600–7,600	6,043	85.4	3.7	79.7–92.1	7,200	3.7	6,700–7,700	6,179	85.7	3.7	79.9–92.4
Wyoming	370	15.1	320–480	322	86.8	9.7	67.0–100	390	14.7	340–510	343	87.1	9.5	67.6–100

	2019							2020 (COVID-19 pandemic) <sup>a</sup>						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
Alabama	16,300	2.6	15,500–17,200	13,721	84.0	2.6	79.9–88.6	16,600	2.7	15,700–17,500	13,992	84.4	2.7	80.1–89.1
Alaska	840	11.3	710–1,000	711	84.6	9.3	69.2–100	850	11.7	720–1,000	721	84.9	9.3	69.1–100
Arizona	20,200	2.3	19,300–21,100	16,969	83.9	2.3	80.3–87.9	20,700	2.4	19,800–21,700	17,472	84.3	2.4	80.6–88.4
Arkansas	7,300	4.0	6,700–7,900	5,815	79.9	4.1	74.1–86.7	7,500	4.2	6,800–8,100	5,948	79.8	4.3	73.7–87.1
California	151,700	0.9	149,100–154,200	132,153	87.1	0.9	85.7–88.6	152,800	0.9	150,200–155,500	133,497	87.3	0.9	85.8–88.9
Colorado	14,600	2.6	13,900–15,400	12,790	87.5	2.6	83.2–92.2	14,900	2.7	14,100–15,600	13,031	87.7	2.7	83.3–92.5
Connecticut	11,400	3.2	10,600–12,100	10,392	91.5	3.2	86.2–97.6	11,300	3.3	10,600–12,100	10,391	91.7	3.3	86.2–98.0
Delaware	3,800	5.5	3,400–4,200	3,326	87.7	5.5	79.2–98.2	3,900	5.6	3,400–4,300	3,381	87.5	5.7	78.8–98.3
District of Columbia	14,800	2.8	14,000–15,700	13,882	93.5	2.8	88.7–99.0	14,500	2.9	13,700–15,400	13,655	94.0	2.9	88.9–99.6
Florida	129,700	0.9	127,300–132,100	112,068	86.4	0.9	84.8–88.0	130,900	1.0	128,400–133,400	113,398	86.7	1.0	85.0–88.3
Georgia	67,500	1.2	65,900–69,100	56,154	83.2	1.2	81.2–85.3	68,600	1.3	66,800–70,300	57,318	83.6	1.3	81.5–85.8
Hawaii	2,600	6.9	2,300–3,000	2,339	89.4	6.1	78.8–100	2,600	7.1	2,400–3,000	2,351	89.1	6.2	78.2–100
Idaho <sup>c</sup>	1,600	11.5	1,300–2,000	1,215	74.1	12.2	60.5–95.8	1,700	12.2	1,300–2,100	1,244	74.7	12.9	60.3–98.1

	2019							2020 (COVID-19 pandemic) <sup>a</sup>						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
Illinois	40,500	1.7	39,200–41,900	35,248	86.9	1.7	84.1–89.9	40,600	1.8	39,200–42,000	35,390	87.2	1.8	84.3–90.3
Indiana	13,600	2.8	12,900–14,400	11,430	83.8	2.8	79.3–88.7	14,000	3.0	13,200–14,800	11,692	83.6	3.0	79.0–88.7
Iowa	3,400	5.3	3,000–3,700	2,832	84.0	5.3	76.2–93.7	3,400	5.5	3,000–3,800	2,887	84.4	5.6	76.1–94.7
Kansas	3,800	5.6	3,300–4,200	3,104	82.7	5.7	74.6–92.9	3,900	5.6	3,500–4,400	3,264	83.0	5.7	74.7–93.3
Kentucky	9,100	3.3	8,500–9,700	7,456	81.9	3.4	76.9–87.7	9,400	3.5	8,800–10,100	7,761	82.4	3.5	77.2–88.4
Louisiana	25,000	2.2	23,900–26,100	20,964	83.9	2.2	80.5–87.7	25,200	2.3	24,000–26,300	21,131	84.0	2.3	80.4–87.9
Maine	1,800	7.8	1,600–2,100	1,619	88.2	6.8	76.5–100	1,800	8.0	1,600–2,100	1,626	88.4	6.8	76.3–100
Maryland	36,400	1.8	35,200–37,700	32,785	90.0	1.8	87.0–93.2	36,400	1.8	35,200–37,700	32,922	90.3	1.8	87.2–93.6
Massachusetts	22,400	2.1	21,500–23,400	20,526	91.5	2.1	87.8–95.5	22,500	2.2	21,600–23,500	20,671	91.8	2.2	88.0–95.8
Michigan	19,100	2.5	18,100–20,000	16,367	85.9	2.5	81.9–90.3	19,300	2.6	18,400–20,300	16,642	86.0	2.6	81.9–90.6
Minnesota	9,900	3.1	9,300–10,500	8,679	87.7	3.1	82.7–93.3	10,000	3.1	9,400–10,700	8,858	88.1	3.2	83.0–93.9
Mississippi <sup>d</sup>	11,400	3.3	10,700–12,200	9,528	83.4	3.3	78.3–89.2	11,500	3.5	10,700–12,300	9,554	83.1	3.5	77.7–89.2
Missouri	14,500	2.7	13,800–15,300	12,667	87.1	2.7	82.7–92.0	14,600	2.8	13,800–15,400	12,755	87.4	2.8	82.8–92.5
Montana	710	10.3	650–860	652	91.4	6.7	76.0–100	740	10.2	680–890	680	92.0	6.5	76.7–100
Nebraska	2,600	6.3	2,200–2,900	2,184	85.2	6.4	75.9–97.2	2,700	6.4	2,400–3,000	2,287	84.8	6.5	75.4–97.0
Nevada	12,900	2.8	12,200–13,600	10,538	81.8	2.8	77.6–86.6	13,300	3.0	12,600–14,100	10,889	81.6	3.0	77.1–86.6
New Hampshire	1,400	8.4	1,300–1,700	1,275	89.8	6.5	77.1–100	1,400	8.6	1,300–1,700	1,295	90.4	6.4	77.4–100
New Jersey <sup>c</sup>	38,700	2.0	37,200–40,200	34,282	88.6	2.0	85.4–92.2	38,700	2.0	37,200–40,200	34,376	88.9	2.0	85.5–92.5
New Mexico	4,300	4.5	3,900–4,700	3,754	87.4	4.6	80.2–95.9	4,400	4.6	4,000–4,800	3,867	87.5	4.7	80.2–96.3
New York	132,800	0.9	130,400–135,200	123,173	92.7	0.9	91.1–94.5	131,600	1.0	129,100–134,100	122,311	92.9	1.0	91.2–94.7
North Carolina	37,900	1.6	36,700–39,100	32,577	86.0	1.6	83.4–88.9	38,300	1.7	37,000–39,500	33,118	86.5	1.7	83.8–89.5
North Dakota	740	14.3	530–950	486	65.6	15.5	51.3–91.3	760	15.0	540–980	515	67.7	16.4	52.4–95.9
Ohio	26,900	2.0	25,800–27,900	22,874	85.1	2.0	81.9–88.5	27,300	2.0	26,200–28,300	23,327	85.6	2.0	82.3–89.1
Oklahoma	7,800	3.9	7,300–8,400	6,321	80.5	3.9	74.9–87.1	8,100	4.0	7,400–8,700	6,550	81.0	4.0	75.1–87.9
Oregon	8,000	3.4	7,500–8,600	7,183	89.6	3.4	84.0–96.0	8,100	3.5	7,500–8,700	7,269	89.6	3.5	83.8–96.3
Pennsylvania <sup>c</sup>	39,800	1.7	38,500–41,100	35,721	89.8	1.7	87.0–92.9	39,900	1.7	38,500–41,200	35,860	90.0	1.7	87.0–93.1

	2019							2020 (COVID-19 pandemic) <sup>a</sup>						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
Puerto Rico <sup>c,d</sup>	17,300	3.1	16,200–18,300	15,556	90.1	3.1	85.0–96.0	17,100	3.2	16,000–18,200	15,496	90.6	3.2	85.3–96.7
Rhode Island	2,900	5.8	2,600–3,200	2,611	91.2	5.1	81.8–100	2,900	6.0	2,600–3,200	2,617	91.0	5.2	81.5–100
South Carolina	20,500	2.4	19,600–21,500	17,236	84.0	2.4	80.2–88.1	20,900	2.5	19,800–21,900	17,568	84.3	2.5	80.4–88.5
South Dakota	800	12.5	640–1,000	636	79.2	11.7	63.6–100	860	12.9	680–1,100	679	78.7	12.1	62.8–100
Tennessee	20,700	2.3	19,700–21,600	17,641	85.3	2.3	81.7–89.3	21,100	2.3	20,100–22,100	18,158	86.0	2.3	82.3–90.2
Texas	113,300	1.0	111,100–115,500	94,185	83.1	1.0	81.6–84.8	115,900	1.0	113,600–118,200	96,755	83.5	1.0	81.9–85.2
Utah	3,700	5.4	3,300–4,100	3,055	83.0	5.4	75.1–92.8	3,900	5.4	3,400–4,300	3,232	83.8	5.5	75.7–93.8
Vermont	750	10.2	690–900	694	92.5	6.3	77.1–100	750	10.4	700–900	697	92.8	6.3	77.0–100
Virginia	26,900	2.1	25,800–28,000	23,253	86.4	2.1	83.1–90.0	27,200	2.1	26,000–28,300	23,563	86.7	2.1	83.3–90.5
Washington	15,800	2.5	15,000–16,600	13,788	87.3	2.6	83.1–91.9	16,100	2.6	15,300–16,900	14,110	87.5	2.6	83.3–92.3
West Virginia	2,600	7.2	2,300–3,000	1,990	75.7	7.3	66.4–88.2	2,800	7.6	2,400–3,200	2,099	75.4	7.8	65.6–88.7
Wisconsin	7,400	3.7	6,900–8,000	6,376	86.0	3.8	80.1–92.8	7,600	3.9	7,000–8,200	6,534	85.7	3.9	79.6–92.7
Wyoming	390	15.5	340–510	340	87.6	9.6	67.2–100	390	16.2	350–520	348	88.5	9.5	67.2–100

	2021 <sup>a</sup>						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
Alabama	17,000	2.8	16,100–17,900	14,313	84.3	2.8	79.9–89.2
Alaska	860	12.1	740–1,100	743	86.7	8.8	70.0–100
Arizona	21,400	2.5	20,300–22,400	18,056	84.6	2.5	80.7–88.9
Arkansas	7,800	4.4	7,100–8,400	6,178	79.7	4.5	73.3–87.3
California	154,300	0.9	151,500–157,100	135,306	87.7	0.9	86.1–89.3
Colorado	15,300	2.8	14,400–16,100	13,328	87.3	2.8	82.9–92.3
Connecticut	11,400	3.3	10,600–12,100	10,466	92.0	3.3	86.4–98.5
Delaware	3,900	5.8	3,500–4,400	3,471	87.9	5.9	78.9–99.1
District of Columbia	14,300	3.0	13,500–15,200	13,504	94.2	3.0	89.0–100
Florida	133,000	1.0	130,400–135,600	115,906	87.1	1.0	85.4–88.9
Georgia	70,100	1.4	68,200–72,000	58,899	84.0	1.4	81.8–86.3
Hawaii	2,700	7.3	2,400–3,000	2,369	89.1	6.3	78.0–100
Idaho <sup>c</sup>	1,700	12.9	1,300–2,100	1,285	75.7	13.4	60.4–100
Illinois	40,500	1.8	39,000–42,000	35,388	87.4	1.8	84.3–90.7
Indiana	14,500	3.0	13,700–15,400	12,208	84.0	3.0	79.3–89.2
Iowa	3,500	5.7	3,200–3,900	3,009	84.8	5.8	76.2–95.5
Kansas	4,100	5.7	3,700–4,600	3,446	83.8	5.8	75.3–94.4
Kentucky	9,800	3.6	9,100–10,400	8,066	82.7	3.7	77.2–89.1

	2021 <sup>a</sup>						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
Louisiana	25,300	2.4	24,200–26,500	21,376	84.4	2.4	80.6–88.5
Maine	1,900	8.2	1,700–2,200	1,670	89.0	6.7	76.6–100
Maryland	36,400	1.8	35,000–37,700	32,944	90.6	1.9	87.4–94.0
Massachusetts	22,600	2.2	21,600–23,600	20,793	92.0	2.2	88.1–96.1
Michigan	19,800	2.6	18,800–20,800	17,115	86.4	2.6	82.2–91.1
Minnesota	10,200	3.2	9,600–10,900	9,086	88.7	3.2	83.4–94.7
Mississippi <sup>d</sup>	11,700	3.7	10,900–12,600	9,764	83.2	3.7	77.6–89.6
Missouri	14,800	2.9	14,000–15,700	12,999	87.6	2.9	82.9–92.9
Montana	780	10.1	720–930	717	91.9	6.5	76.7–100
Nebraska	2,800	6.7	2,400–3,100	2,348	84.8	6.8	75.0–97.6
Nevada	13,800	3.1	13,000–14,700	11,336	82.0	3.1	77.3–87.3
New Hampshire	1,500	8.6	1,300–1,700	1,339	90.6	6.3	77.5–100
New Jersey <sup>c</sup>	39,000	2.1	37,400–40,600	34,636	88.8	2.1	85.3–92.6
New Mexico	4,600	4.7	4,100–5,000	3,990	87.7	4.8	80.2–96.7
New York	131,100	1.0	128,500–133,600	122,136	93.2	1.0	91.4–95.0
North Carolina	38,900	1.7	37,600–40,200	33,947	87.2	1.7	84.4–90.3
North Dakota	800	16.0	550–1,100	533	66.5	17.8	50.6–97.0
Ohio	27,700	2.1	26,600–28,900	23,842	86.0	2.1	82.6–89.6
Oklahoma	8,400	4.1	7,700–9,100	6,878	81.7	4.2	75.6–88.9
Oregon	8,300	3.7	7,700–8,900	7,433	89.6	3.7	83.6–96.6
Pennsylvania <sup>c</sup>	40,100	1.8	38,700–41,500	36,287	90.5	1.8	87.5–93.8
Puerto Rico <sup>c,d</sup>	17,100	3.2	16,000–18,200	15,579	91.1	3.3	85.7–97.3
Rhode Island	2,900	6.1	2,700–3,300	2,663	91.6	5.0	81.9–100
South Carolina	21,200	2.6	20,100–22,300	17,914	84.5	2.6	80.5–89.0
South Dakota	910	13.5	710–1,100	708	78.1	12.5	61.7–100
Tennessee	21,400	2.4	20,400–22,400	18,554	86.6	2.4	82.7–90.9
Texas	119,000	1.0	116,500–121,400	99,947	84.0	1.0	82.3–85.8
Utah	4,000	5.6	3,600–4,500	3,409	84.4	5.7	76.0–94.8
Vermont	760	10.4	710–920	714	93.5	6.1	77.6–100
Virginia	27,600	2.2	26,500–28,800	24,143	87.3	2.2	83.8–91.2
Washington	16,500	2.7	15,600–17,300	14,445	87.8	2.7	83.3–92.7
West Virginia	2,900	8.3	2,400–3,300	2,172	76.1	8.5	65.4–90.8
Wisconsin	7,800	4.0	7,200–8,400	6,753	86.2	4.0	79.9–93.5
Wyoming	420	16.2	370–550	368	88.6	9.4	67.2–100

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage [footnotes only].

Note. Estimates for the year 2021 data are preliminary and based on deaths reported to CDC as of December 2022. Estimates derived by using HIV surveillance data and CD4 data for persons aged  $\geq 13$  years at diagnosis.

Estimates rounded to the nearest 100 for estimates  $> 1,000$  and to the nearest 10 for estimates  $\leq 1,000$  to reflect the uncertainty.

<sup>a</sup> Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of Estimated HIV Incidence and Prevalence in the United States, 2017–2021 for more information.

<sup>b</sup> Reported to the National HIV Surveillance System.

<sup>c</sup> Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data

or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

<sup>d</sup> Estimates should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.

**Table 2c. Estimated HIV prevalence among persons aged  $\geq 13$  years, by area of residence, 2017–2021—Ending the HIV Epidemic Phase I jurisdictions**

	2017							2018						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
<b>Arizona</b>														
Maricopa County	13,000	2.7	12,300–13,600	10,672	82.4	2.7	78.2	13,400	2.8	12,700–14,100	11,101	82.8	2.8	78.6–87.6
<b>California</b>														
Alameda County	6,700	4.0	6,200–7,200	5,813	86.8	4.0	80.5	6,900	4.0	6,300–7,400	5,984	87.3	4.0	81.0–94.7
Los Angeles County	54,300	1.4	52,800–55,800	47,840	88.1	1.4	85.7	54,900	1.4	53,400–56,400	48,646	88.6	1.4	86.2–91.1
Orange County	8,100	3.6	7,600–8,700	6,719	82.5	3.6	77.0	8,200	3.7	7,600–8,800	6,824	82.8	3.7	77.3–89.3
Riverside County	9,600	2.6	9,100–10,100	8,455	88.4	2.6	84.1	10,100	2.6	9,600–10,600	9,000	88.8	2.6	84.6–93.5
Sacramento County	5,000	4.3	4,500–5,400	4,173	84.1	4.3	77.5	5,100	4.3	4,700–5,600	4,303	83.8	4.4	77.3–91.6
San Bernardino County	5,300	4.3	4,800–5,700	4,092	77.4	4.3	71.3	5,600	4.2	5,200–6,100	4,422	78.7	4.3	72.7–85.8
San Diego County	14,900	2.6	14,100–15,600	12,848	86.4	2.6	82.2	15,100	2.6	14,300–15,900	13,032	86.3	2.6	82.1–90.9
San Francisco County	12,800	3.4	12,300–13,700	12,279	95.6	2.8	89.7	12,600	3.5	12,100–13,400	12,093	96.2	2.7	90.0–100
<b>District of Columbia</b>	15,100	2.7	14,300–15,900	14,039	93.0	2.7	88.4	14,900	2.7	14,100–15,700	13,917	93.2	2.7	88.5–98.5
<b>Florida</b>														
Broward County	21,400	2.1	20,600–22,300	19,045	88.8	2.1	85.3	21,700	2.1	20,800–22,600	19,334	89.2	2.1	85.6–93.1
Duval County	7,100	3.9	6,500–7,600	5,834	82.4	3.9	76.6	7,200	3.9	6,700–7,800	6,018	83.1	3.9	77.2–90.0
Hillsborough County	7,900	3.6	7,300–8,500	6,628	83.8	3.7	78.2	8,000	3.7	7,500–8,600	6,775	84.2	3.7	78.5–90.8
Miami-Dade County	29,500	2.0	28,400–30,700	25,649	86.8	2.0	83.5	29,800	2.0	28,600–31,000	25,960	87.1	2.0	83.8–90.7
Orange County	10,100	3.2	9,500–10,700	8,298	82.3	3.2	77.5	10,300	3.2	9,700–11,000	8,555	83.0	3.2	78.1–88.6
Palm Beach County	8,900	3.6	8,300–9,600	7,724	86.6	3.6	80.9	9,000	3.7	8,300–9,600	7,779	86.8	3.7	81.0–93.5
Pinellas County	5,200	4.3	4,800–5,700	4,488	85.8	4.3	79.2	5,200	4.4	4,800–5,700	4,524	86.5	4.4	79.7–94.7
<b>Georgia</b>														
Cobb County	3,700	4.6	3,400–4,000	2,994	80.9	4.7	74.1	3,900	4.7	3,500–4,200	3,162	81.7	4.7	74.8–89.9
DeKalb County	9,600	3.1	9,000–10,200	8,108	84.1	3.2	79.3	10,000	3.1	9,400–10,600	8,455	84.4	3.2	79.5–89.9

	2017							2018						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
Fulton County	16,800	2.4	16,000–17,600	14,230	84.9	2.4	81.1	17,600	2.4	16,800–18,400	15,043	85.5	2.4	81.7–89.6
Gwinnett County	3,400	4.5	3,100–3,700	2,716	79.4	4.5	73.0	3,500	4.6	3,200–3,900	2,843	80.2	4.6	73.6–88.1
<b>Illinois</b>														
Cook County	28,300	2.0	27,200–29,400	24,537	86.6	2.0	83.3	28,500	2.0	27,400–29,700	24,833	87.1	2.0	83.7–90.7
<b>Indiana</b>														
Marion County	5,300	4.2	4,900–5,700	4,475	84.6	4.2	78.1	5,400	4.2	5,000–5,900	4,605	84.7	4.3	78.2–92.3
<b>Louisiana</b>														
East Baton Rouge Parish	4,500	4.8	4,000–4,900	3,788	84.9	4.8	77.6	4,500	4.9	4,100–5,000	3,852	85.1	4.9	77.7–94.1
Orleans Parish	5,300	5.1	4,800–5,900	4,729	88.5	5.1	80.5	5,400	5.1	4,900–5,900	4,822	89.1	5.1	81.1–99.0
<b>Maryland</b>														
Baltimore City	11,800	3.3	11,000–12,500	10,855	92.2	3.3	86.5	10,900	3.6	10,200–11,700	10,034	91.8	3.7	85.6–98.8
Montgomery County	4,200	4.7	3,900–4,600	3,770	88.8	4.8	81.2	4,300	4.8	3,900–4,700	3,829	89.6	4.9	81.9–98.9
Prince George's County	8,800	3.3	8,200–9,400	7,579	86.0	3.3	80.9	9,000	3.3	8,400–9,600	7,839	86.9	3.3	81.7–92.9
<b>Massachusetts</b>														
Suffolk County	6,100	4.2	5,700–6,600	5,671	93.1	3.8	86.0	6,000	4.3	5,600–6,500	5,620	93.4	3.8	86.2–100
<b>Michigan</b>														
Wayne County	7,500	4.1	6,900–8,100	6,357	84.8	4.2	78.4	7,800	4.1	7,100–8,400	6,656	85.8	4.1	79.4–93.3
<b>Nevada</b>														
Clark County	9,800	3.0	9,200–10,400	7,935	80.9	3.0	76.4	10,400	3.0	9,800–11,000	8,448	81.3	3.0	76.8–86.3
<b>New Jersey</b>														
Essex County <sup>c</sup>	9,900	3.9	9,100–10,600	8,879	89.7	3.9	83.4	9,800	4.0	9,100–10,600	8,843	90.1	4.0	83.6–97.7
Hudson County <sup>c</sup>	5,400	5.1	4,900–6,000	4,752	87.2	5.2	79.3	5,500	5.2	4,900–6,000	4,768	87.5	5.3	79.4–97.4
<b>New York</b>														
Bronx County	28,300	1.8	27,300–29,300	26,493	93.6	1.8	90.5	28,400	1.8	27,400–29,400	26,690	93.9	1.8	90.7–97.3
Kings County	27,700	2.0	26,600–28,800	25,567	92.4	2.0	88.9	27,700	2.0	26,600–28,800	25,727	92.8	2.0	89.2–96.6
New York County	28,200	2.1	27,000–29,300	26,536	94.2	2.1	90.5	28,100	2.1	26,900–29,300	26,527	94.4	2.1	90.6–98.6
Queens County	16,900	2.5	16,100–17,800	15,303	90.4	2.5	86.2	17,100	2.5	16,200–17,900	15,528	91.0	2.5	86.8–95.7
<b>North Carolina</b>														
Mecklenburg County	6,500	3.8	6,000–7,000	5,598	85.9	3.8	80.0	6,700	3.7	6,200–7,200	5,800	86.3	3.8	80.4–93.1
<b>Ohio</b>														

	2017							2018						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
Cuyahoga County	5,300	4.2	4,900–5,700	4,557	86.0	4.2	79.5	5,400	4.2	4,900–5,800	4,670	86.6	4.3	80.0–94.5
Franklin County	5,500	4.1	5,100–6,000	4,704	85.0	4.1	78.7	5,600	4.1	5,100–6,000	4,758	85.1	4.2	78.7–92.6
Hamilton County	3,600	5.1	3,200–3,900	2,856	80.1	5.2	72.7	3,600	5.3	3,200–3,900	2,889	81.2	5.4	73.5–90.7
<b>Pennsylvania</b>														
Philadelphia County	18,300	2.4	17,400–19,100	16,746	91.7	2.4	87.6	18,200	2.4	17,300–19,000	16,688	91.8	2.4	87.7–96.4
<b>Puerto Rico</b>														
San Juan Municipio <sup>c</sup>	3,600	7.1	3,200–4,100	3,207	89.0	6.3	78.0	3,600	7.2	3,200–4,100	3,248	90.0	6.0	78.8–100
<b>Tennessee</b>														
Shelby County	7,100	3.8	6,500–7,600	6,031	85.2	3.9	79.2	7,300	3.8	6,800–7,800	6,291	86.2	3.8	80.2–93.1
<b>Texas</b>														
Bexar County	7,300	3.6	6,800–7,900	6,074	82.7	3.7	77.2	7,500	3.7	7,000–8,100	6,253	83.2	3.7	77.6–89.7
Dallas County	20,800	2.2	19,900–21,700	17,319	83.2	2.2	79.8	21,500	2.2	20,600–22,400	17,966	83.6	2.2	80.2–87.3
Harris County	29,700	1.9	28,600–30,700	24,623	83.0	1.9	80.1	30,400	1.9	29,200–31,500	25,422	83.7	1.9	80.7–86.9
Tarrant County	6,600	3.7	6,100–7,100	5,405	81.7	3.7	76.1	6,900	3.7	6,300–7,400	5,636	82.3	3.8	76.6–88.8
Travis County	5,600	4.2	5,200–6,100	4,693	83.4	4.2	77.1	5,900	4.2	5,400–6,300	4,883	83.3	4.2	77.0–90.7
<b>Washington</b>														
King County	7,700	3.7	7,200–8,300	6,745	87.1	3.7	81.2	7,800	3.8	7,200–8,400	6,805	87.5	3.8	81.4–94.5

	2019							2020 (COVID-19 pandemic) <sup>a</sup>						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
<b>Arizona</b>														
Maricopa County	13,900	2.8	13,100–14,600	11,561	83.4	2.8	79.0–88.2	14,200	2.9	13,400–15,000	11,926	84.0	2.9	79.5–89.1
<b>California</b>														
Alameda County	6,900	4.1	6,300–7,400	6,038	87.6	4.1	81.1–95.2	6,800	4.3	6,200–7,400	5,965	87.9	4.3	81.1–95.9
Los Angeles County	55,500	1.4	54,000–57,100	49,420	89.0	1.4	86.5–91.5	55,700	1.5	54,100–57,300	49,814	89.4	1.5	86.9–92.0
Orange County	8,300	3.7	7,700–8,900	6,917	83.2	3.8	77.5–89.8	8,400	3.8	7,800–9,000	7,034	83.6	3.9	77.8–90.5
Riverside County	10,500	2.6	10,000–11,000	9,367	89.3	2.6	85.0–94.0	10,800	2.6	10,300–11,400	9,709	89.5	2.6	85.1–94.4
Sacramento County	5,300	4.4	4,800–5,700	4,412	83.5	4.4	76.9–91.3	5,400	4.5	4,900–5,900	4,534	83.8	4.5	77.0–91.9
San Bernardino County	5,900	4.3	5,400–6,400	4,692	79.4	4.3	73.3–86.7	6,000	4.5	5,500–6,600	4,803	79.7	4.5	73.3–87.4

	2019							2020 (COVID-19 pandemic) <sup>a</sup>						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
San Diego County	15,300	2.7	14,500–16,100	13,176	86.3	2.7	82.1–91.1	15,400	2.7	14,600–16,200	13,299	86.4	2.7	82.1–91.3
San Francisco County	12,400	3.6	12,000–13,200	11,972	96.9	2.5	90.5–100	12,100	3.7	11,800–13,000	11,781	97.2	2.5	90.6–100
District of Columbia	14,800	2.8	14,000–15,700	13,882	93.5	2.8	88.7–99.0	14,500	2.9	13,700–15,400	13,655	94.0	2.9	88.9–99.6
<b>Florida</b>														
Broward County	22,000	2.2	21,000–22,900	19,650	89.4	2.2	85.7–93.4	22,100	2.2	21,100–23,100	19,811	89.6	2.2	85.8–93.7
Duval County	7,300	4.0	6,700–7,900	6,152	84.1	4.0	78.0–91.2	7,400	4.1	6,800–8,000	6,266	84.4	4.1	78.1–91.8
Hillsborough County	8,200	3.7	7,600–8,800	6,989	84.8	3.7	79.1–91.4	8,400	3.8	7,800–9,000	7,176	85.2	3.8	79.3–92.1
Miami-Dade County	29,900	2.1	28,700–31,200	26,186	87.4	2.1	84.0–91.2	30,000	2.2	28,700–31,200	26,269	87.6	2.2	84.1–91.5
Orange County	10,500	3.3	9,800–11,200	8,759	83.3	3.3	78.2–89.0	10,600	3.4	9,900–11,400	8,892	83.5	3.5	78.2–89.5
Palm Beach County	9,100	3.7	8,400–9,700	7,864	86.8	3.7	80.9–93.6	9,200	3.8	8,500–9,900	7,925	86.3	3.8	80.3–93.3
Pinellas County	5,400	4.4	4,900–5,900	4,731	87.6	4.4	80.7–95.7	5,500	4.5	5,000–6,000	4,836	88.3	4.5	81.1–96.8
<b>Georgia</b>														
Cobb County	4,000	4.8	3,700–4,400	3,324	82.1	4.8	75.1–90.6	4,200	5.0	3,800–4,600	3,481	82.5	5.0	75.2–91.4
DeKalb County	10,400	3.2	9,700–11,000	8,823	85.1	3.2	80.1–90.7	10,500	3.3	9,800–11,200	8,964	85.5	3.3	80.3–91.4
Fulton County	18,100	2.4	17,300–19,000	15,572	85.9	2.4	82.1–90.1	18,500	2.5	17,600–19,400	15,937	86.1	2.5	82.2–90.5
Gwinnett County	3,700	4.7	3,400–4,100	3,039	81.5	4.8	74.6–89.9	3,800	5.0	3,400–4,200	3,177	83.2	5.0	75.8–92.2
<b>Illinois</b>														
Cook County	29,100	2.0	27,900–30,200	25,486	87.6	2.0	84.3–91.3	29,200	2.1	28,000–30,400	25,639	87.8	2.1	84.3–91.6
<b>Indiana</b>														
Marion County	5,500	4.4	5,000–5,900	4,605	84.2	4.4	77.6–92.2	5,600	4.5	5,100–6,100	4,726	84.2	4.6	77.3–92.4
<b>Louisiana</b>														
East Baton Rouge Parish	4,600	5.0	4,100–5,000	3,886	85.0	5.1	77.4–94.3	4,700	5.0	4,200–5,200	4,051	86.0	5.1	78.3–95.4
Orleans Parish	5,500	5.1	4,900–6,000	4,913	89.8	5.2	81.6–99.8	5,400	5.3	4,900–6,000	4,886	89.9	5.2	81.5–100
<b>Maryland</b>														
Baltimore City	10,900	3.7	10,100–11,700	10,025	92.3	3.7	86.0–99.5	10,500	3.9	9,700–11,300	9,725	92.2	3.9	85.7–99.8
Montgomery County	4,300	4.9	3,900–4,700	3,868	90.4	5.0	82.4–100	4,200	5.1	3,800–4,600	3,825	90.7	4.9	82.4–100
Prince George's County	9,100	3.4	8,500–9,700	7,929	87.5	3.4	82.1–93.6	9,000	3.5	8,400–9,600	7,973	88.3	3.5	82.7–94.7
<b>Massachusetts</b>														
Suffolk County	6,000	4.3	5,600–6,500	5,624	93.6	3.7	86.3–100	6,000	4.4	5,600–6,500	5,632	93.6	3.8	86.2–100

	2019							2020 (COVID-19 pandemic) <sup>a</sup>						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
<b>Michigan</b>														
Wayne County	8,000	4.1	7,300–8,600	6,868	86.3	4.1	79.9–93.8	8,000	4.2	7,400–8,700	6,940	86.3	4.2	79.7–94.1
<b>Nevada</b>														
Clark County	10,900	3.0	10,200–11,500	8,893	81.8	3.0	77.2–86.9	11,300	3.2	10,600–12,000	9,252	81.5	3.2	76.8–86.9
<b>New Jersey</b>														
Essex County <sup>c</sup>	9,800	4.0	9,000–10,600	8,853	90.4	4.1	83.8–98.2	9,700	4.2	8,900–10,500	8,768	90.6	4.2	83.7–98.7
Hudson County <sup>c</sup>	5,500	5.3	4,900–6,000	4,808	88.2	5.4	79.9–98.4	5,400	5.5	4,800–6,000	4,799	88.5	5.6	79.9–99.3
<b>New York</b>														
Bronx County	28,700	1.8	27,700–29,700	27,121	94.4	1.8	91.2–97.8	28,400	1.8	27,400–29,400	26,797	94.3	1.8	91.0–97.9
Kings County	27,700	2.1	26,600–28,800	25,730	93.0	2.1	89.4–96.9	27,400	2.1	26,200–28,500	25,541	93.3	2.1	89.6–97.4
New York County	27,800	2.2	26,600–29,000	26,340	94.6	2.2	90.7–98.8	27,400	2.2	26,200–28,600	25,945	94.7	2.2	90.7–99.0
Queens County	17,200	2.5	16,300–18,000	15,728	91.7	2.5	87.3–96.5	17,100	2.6	16,200–17,900	15,716	92.1	2.6	87.6–97.0
<b>North Carolina</b>														
Mecklenburg County	7,000	3.8	6,500–7,500	6,023	86.4	3.8	80.5–93.3	7,100	3.9	6,500–7,600	6,127	86.7	3.9	80.5–93.8
<b>Ohio</b>														
Cuyahoga County	5,400	4.3	5,000–5,900	4,752	87.3	4.3	80.5–95.3	5,500	4.4	5,000–6,000	4,850	87.7	4.4	80.8–96.0
Franklin County	5,800	4.1	5,300–6,300	4,991	85.8	4.2	79.3–93.4	5,900	4.2	5,400–6,400	5,132	86.5	4.3	79.9–94.3
Hamilton County	3,600	5.4	3,300–4,000	3,024	83.0	5.5	75.0–92.8	3,700	5.6	3,300–4,100	3,083	83.4	5.6	75.2–93.6
<b>Pennsylvania</b>														
Philadelphia County	18,300	2.4	17,400–19,200	16,848	92.1	2.4	87.9–96.7	18,000	2.5	17,100–18,900	16,651	92.4	2.5	88.0–97.2
<b>Puerto Rico</b>														
San Juan Municipio <sup>c</sup>	3,700	7.2	3,300–4,200	3,309	90.4	5.8	79.3–100	3,700	7.2	3,400–4,200	3,392	91.3	5.6	80.0–100
<b>Tennessee</b>														
Shelby County	7,400	3.9	6,800–7,900	6,332	86.0	3.9	79.9–93.2	7,200	4.1	6,600–7,800	6,246	86.7	4.1	80.3–94.4
<b>Texas</b>														
Bexar County	7,800	3.7	7,200–8,400	6,500	83.3	3.8	77.6–89.9	8,100	3.9	7,500–8,700	6,727	83.3	3.9	77.4–90.2
Dallas County	21,900	2.2	21,000–22,900	18,499	84.4	2.2	80.9–88.2	22,300	2.3	21,300–23,300	18,953	84.9	2.3	81.3–88.8
Harris County	31,200	1.9	20,100–32,400	26,367	84.4	1.9	81.3–87.7	31,800	2.0	30,500–33,000	26,897	84.7	2.0	81.5–88.1
Tarrant County	7,200	3.8	6,600–7,700	5,882	82.1	3.8	76.4–88.7	7,400	3.9	6,900–8,000	6,144	82.6	4.0	76.6–89.5
Travis County	6,000	4.2	5,500–6,500	5,024	83.7	4.3	77.3–91.2	6,100	4.3	5,600–6,600	5,138	84.3	4.4	77.7–92.1

	2019							2020 (COVID-19 pandemic) <sup>a</sup>							
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection				
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	
<b>Washington</b>															
King County	7,900	3.9	7,300–8,500	6,969	88.0	3.9	81.8–95.2	8,000	4.0	7,300–8,600	7,024	88.1	4.0	81.7–95.6	
<b>2021<sup>a</sup></b>															
<b>Persons living with diagnosed or undiagnosed HIV infection</b>															
<b>Persons living with diagnosed HIV infection</b>															
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
<b>Arizona</b>															
Maricopa County	14,500	3.0	13,700–15,400	12,286	84.6	3.0	79.8–89.9								
<b>California</b>															
Alameda County	6,800	4.4	6,200–7,300	5,950	88.0	4.5	81.0–96.4								
Los Angeles County	55,800	1.5	54,200–57,500	50,182	89.9	1.5	87.3–92.7								
Orange County	8,500	3.9	7,900–9,200	7,181	84.2	4.0	78.1–91.3								
Riverside County	11,200	2.7	10,600–11,800	10,089	90.0	2.7	85.5–94.9								
Sacramento County	5,400	4.6	4,900–5,900	4,610	84.8	4.7	77.7–93.3								
San Bernardino County	6,200	4.6	5,600–6,800	5,009	80.6	4.7	73.9–88.7								
San Diego County	15,600	2.8	14,700–16,400	13,442	86.3	2.8	81.8–91.3								
San Francisco County	11,900	3.8	11,600–12,800	11,601	97.5	2.4	90.7–100								
<b>District of Columbia</b>	14,300	3.0	13,500–15,200	13,504	94.2	3.0	89.0–100								
<b>Florida</b>															
Broward County	22,400	2.3	21,400–23,400	20,137	90.0	2.3	86.1–94.2								
Duval County	7,500	4.2	6,900–8,100	6,413	85.3	4.3	78.8–93.0								
Hillsborough County	8,500	3.9	7,900–9,200	7,379	86.7	3.9	80.6–93.8								
Miami-Dade County	30,500	2.2	29,200–31,800	26,875	88.1	2.2	84.4–92.0								
Orange County	11,100	3.5	10,300–11,800	9,252	83.7	3.5	78.3–89.9								
Palm Beach County	9,300	3.9	8,500–10,000	8,034	86.8	3.9	80.7–94.0								
Pinellas County	5,500	4.6	5,000–6,000	4,895	88.9	4.6	81.5–97.7								
<b>Georgia</b>															
Cobb County	4,300	5.1	3,900–4,800	3,623	83.8	5.2	76.1–93.1								
DeKalb County	10,600	3.5	9,800–11,300	9,064	85.8	3.5	80.4–92.0								
Fulton County	18,900	2.5	17,900–19,800	16,290	86.3	2.6	82.2–90.9								
Gwinnett County	3,900	5.2	3,500–4,300	3,315	84.6	5.3	76.7–94.3								
<b>Illinois</b>															
Cook County	29,000	2.2	27,800–30,300	25,493	87.9	2.2	84.3–91.9								
<b>Indiana</b>															
Marion County	5,800	4.6	5,300–6,300	4,927	84.8	4.7	77.7–93.2								
<b>Louisiana</b>															
East Baton Rouge Parish	4,700	5.2	4,200–5,200	4,086	86.7	5.2	78.7–96.5								
Orleans Parish	5,400	5.5	4,800–5,900	4,822	90.0	5.3	81.3–100								
<b>Maryland</b>															
Baltimore City	10,900	3.8	10,100–11,700	10,109	92.5	3.8	86.1–100								
Montgomery County	4,300	5.2	3,900–4,700	3,889	91.3	4.8	82.9–100								
Prince George's County	9,000	3.6	8,400–9,600	7,959	88.5	3.6	82.7–95.3								
<b>Massachusetts</b>															

	2021 <sup>a</sup>						
	Persons living with diagnosed or undiagnosed HIV infection			Persons living with diagnosed HIV infection			
	No.	RSE	95% CI	No. <sup>b</sup>	%	RSE	95% CI
Suffolk County	6,000	4.5	5,600–6,500	5,594	93.6	3.8	86.1–100
<b>Michigan</b>							
Wayne County	8,300	4.2	7,600–8,900	7,180	87.0	4.3	80.3–94.9
<b>Nevada</b>							
Clark County	11,700	3.3	11,000–12,500	9,630	82.0	3.3	77.0–87.7
<b>New Jersey</b>							
Essex County <sup>c</sup>	9,700	4.3	8,800–10,500	8,723	90.2	4.4	83.2–98.6
Hudson County <sup>c</sup>	5,500	5.5	4,900–6,100	4,884	88.7	5.6	80.0–99.5
<b>New York</b>							
Bronx County	28,100	1.9	27,100–29,200	26,554	94.4	1.9	91.0–98.0
Kings County	27,300	2.2	26,100–28,400	25,538	93.6	2.2	89.8–97.7
New York County	27,200	2.3	26,000–28,400	25,805	94.8	2.3	90.8–99.3
Queens County	17,200	2.6	16,300–18,100	15,909	92.5	2.6	88.0–97.6
<b>North Carolina</b>							
Mecklenburg County	7,100	4.0	6,600–7,700	6,227	87.6	4.0	81.2–95.0
<b>Ohio</b>							
Cuyahoga County	5,600	4.6	5,100–6,100	4,923	88.0	4.6	80.8–96.6
Franklin County	6,000	4.4	5,500–6,500	5,214	87.1	4.4	80.2–95.3
Hamilton County	3,700	5.7	3,300–4,100	3,135	84.1	5.8	75.5–94.7
<b>Pennsylvania</b>							
Philadelphia County	17,900	2.6	17,000–18,800	16,546	92.6	2.6	88.1–97.6
<b>Puerto Rico</b>							
San Juan Municipio <sup>c</sup>	3,900	6.9	3,600–4,500	3,622	92.3	5.2	81.3–100
<b>Tennessee</b>							
Shelby County	7,400	4.2	6,800–8,000	6,482	87.8	4.2	81.2–95.6
<b>Texas</b>							
Bexar County	8,200	4.0	7,600–8,900	6,875	83.7	4.1	77.5–90.9
Dallas County	22,900	2.3	21,800–23,900	19,505	85.3	2.4	81.6–89.4
Harris County	32,400	2.0	33,700–27,585	27,585	85.2	2.0	81.9–88.7
Tarrant County	7,700	4.1	8,300–6,346	6,346	82.7	4.1	76.5–89.9
Travis County	6,200	4.5	6,700–5,229	5,229	84.9	4.6	78.0–93.1
<b>Washington</b>							
King County	8,100	4.1	8,700–7,127	7,127	88.4	4.1	81.8–96.2

Abbreviations: RSE, relative standard error; CI, confidence interval; CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage [footnotes only].

Note. Estimates for the year 2021 data are preliminary and based on deaths reported to CDC as of December 2022. Estimates derived by using HIV surveillance data and CD4 data for persons aged  $\geq$  13 years at diagnosis.

Estimates rounded to the nearest 100 for estimates  $>$  1,000 and to the nearest 10 for estimates  $\leq$  1,000 to reflect the uncertainty.

<sup>a</sup> Estimates for years 2020 and 2021 should be interpreted with caution due to adjustments made to the monthly distribution of reported diagnoses during those years to account for the impact of COVID-19 on HIV testing and diagnosis in the United States. See Technical Notes of Estimated HIV Incidence and Prevalence in the United States, 2017–2021 for more information.

<sup>b</sup> Reported to the National HIV Surveillance System.

<sup>c</sup> Estimates should be interpreted with caution because the jurisdiction does not have laws requiring complete reporting of laboratory data or has incomplete reporting. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

**Table 3a. Diagnoses of HIV infection among persons aged  $\geq 13$  years, by selected characteristics, 2017–2022—United States**

	2017	2018	2019	2020 (COVID-19 pandemic) <sup>a</sup>	2021	2022 ( <i>preliminary</i> ) <sup>b</sup>
	No.	No.	No.	No.	No.	No.
<b>Gender</b>						
Male	30,398	29,563	28,779	24,148	28,283	26,095
Female	7,229	7,008	6,873	5,387	6,522	6,018
Transgender woman <sup>c</sup>	651	661	692	676	811	639
Transgender man <sup>c</sup>	32	48	45	41	56	42
Additional gender identity <sup>d</sup>	18	19	32	23	44	52
<b>Age at diagnosis (yr)</b>						
13–24	8,297	7,865	7,660	6,125	6,927	5,961
25–34	13,400	13,346	13,027	11,279	13,081	12,211
35–44	7,235	7,150	7,048	5,874	7,543	7,289
45–54	5,563	5,194	4,874	3,872	4,442	3,991
$\geq 55$	3,833	3,744	3,812	3,125	3,723	3,394
<b>Race/ethnicity</b>						
American Indian/Alaska Native	193	170	193	189	223	186
Asian	911	844	722	610	737	707
Black/African American	16,107	15,593	15,296	12,643	14,522	13,214
Hispanic/Latino <sup>e</sup>	9,995	9,921	9,851	8,037	10,059	9,835
Native Hawaiian/other Pacific Islander	46	57	59	63	76	75
White	9,543	9,323	8,985	7,732	9,058	8,190
Multiracial	1,533	1,391	1,315	1,001	1,041	639
<b>Transmission category<sup>f</sup></b>						
Male-to-male sexual contact <sup>g</sup>	25,345	24,464	23,870	20,460	23,855	22,362
<b>Injection drug use<sup>h</sup></b>						
Male	1,291	1,376	1,362	1,170	1,415	1,231
Female	1,109	1,117	1,182	895	1,075	1,002
Male-to-male sexual contact <sup>g</sup> and injection drug use <sup>h</sup>	1,517	1,531	1,581	1,185	1,373	1,055
<b>Heterosexual contact<sup>i</sup></b>						
Male	2,882	2,839	2,643	2,006	2,460	2,097
Female	6,106	5,892	5,695	4,494	5,456	4,991
<b>Region of residence</b>						
Northeast	5,988	5,552	5,317	4,241	4,988	4,221
Midwest	5,099	4,941	4,767	4,106	4,815	4,284
South	19,645	19,225	18,950	15,537	18,703	17,957
West	7,596	7,581	7,387	6,391	7,210	6,384
<b>Total<sup>j</sup></b>	<b>38,328</b>	<b>37,299</b>	<b>36,421</b>	<b>30,275</b>	<b>35,716</b>	<b>32,846</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through December 2022.

<sup>a</sup> Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

<sup>b</sup> Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

<sup>c</sup> "Transgender woman" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender.

"Transgender man" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender.

<sup>d</sup> Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

<sup>e</sup> Hispanic/Latino persons can be of any race.

<sup>f</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

<sup>g</sup> Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>h</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>i</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>j</sup> Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

**Table 3b. Diagnoses of HIV infection among persons aged  $\geq 13$  years, by selected characteristics, 2017–2022—United States and 6 dependent areas**

	2017	2018	2019	2020 (COVID-19 pandemic) <sup>a</sup>	2021	2022 ( <i>preliminary</i> ) <sup>b</sup>
	No.	No.	No.	No.	No.	No.
<b>Gender</b>						
Male	30,765	29,941	29,118	24,409	28,620	26,374
Female	7,323	7,089	6,956	5,433	6,604	6,077
Transgender woman <sup>c</sup>	653	665	694	679	812	640
Transgender man <sup>c</sup>	32	48	45	41	56	42
Additional gender identity <sup>d</sup>	18	19	32	23	44	52
<b>Age at diagnosis (yr)</b>						
13–24	8,376	7,948	7,724	6,177	6,987	6,006
25–34	13,523	13,482	13,145	11,361	13,204	12,326
35–44	7,323	7,227	7,126	5,940	7,634	7,354
45–54	5,655	5,289	4,943	3,926	4,519	4,046
$\geq 55$	3,914	3,816	3,907	3,181	3,792	3,453
<b>Race/ethnicity</b>						
American Indian/Alaska Native	193	170	193	189	223	186
Asian	914	848	729	610	738	707
Black/African American	16,112	15,605	15,304	12,650	14,528	13,218
Hispanic/Latino <sup>e</sup>	10,441	10,359	10,250	8,338	10,467	10,165
Native Hawaiian/other Pacific Islander	49	59	63	64	76	75
White	9,547	9,329	8,991	7,733	9,063	8,195
Multiracial	1,535	1,392	1,315	1,001	1,041	639
<b>Transmission category<sup>f</sup></b>						
Male-to-male sexual contact <sup>g</sup>	25,587	24,742	24,110	20,660	24,107	22,565
<b>Injection drug use<sup>h</sup></b>						
Male	1,325	1,401	1,385	1,189	1,436	1,255
Female	1,118	1,120	1,188	898	1,077	1,007
Male-to-male sexual contact <sup>g</sup> and injection drug use <sup>h</sup>	1,529	1,542	1,595	1,190	1,375	1,059
<b>Heterosexual contact<sup>i</sup></b>						

	2017	2018	2019	2020 (COVID-19 pandemic) <sup>a</sup>	2021	2022 (preliminary) <sup>b</sup>
	No.	No.	No.	No.	No.	No.
Male	2,963	2,906	2,709	2,046	2,523	2,146
Female	6,190	5,970	5,773	4,536	5,536	5,045
<b>Region of residence</b>						
Northeast	5,988	5,552	5,317	4,241	4,988	4,221
Midwest	5,099	4,941	4,767	4,106	4,815	4,284
South	19,645	19,225	18,950	15,537	18,703	17,957
West	7,596	7,581	7,387	6,391	7,210	6,384
U.S. dependent areas	463	463	424	310	420	339
<b>Total<sup>l</sup></b>	<b>38,791</b>	<b>37,762</b>	<b>36,845</b>	<b>30,585</b>	<b>36,136</b>	<b>33,185</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through December 2022.

<sup>a</sup> Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

<sup>b</sup> Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

<sup>c</sup> “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender.

“Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

<sup>d</sup> Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

<sup>e</sup> Hispanic/Latino persons can be of any race.

<sup>f</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.

<sup>g</sup> Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>h</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>i</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>j</sup> Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

**Table 3c. Diagnoses of HIV infection among persons aged  $\geq$  13 years, by area of residence, 2017–2022—United States and 6 dependent areas**

	2017	2018	2019	2020 (COVID-19 pandemic) <sup>a</sup>	2021	2022 (preliminary) <sup>b</sup>
Area of residence	No.	No.	No.	No.	No.	No.
Alabama	647	606	635	590	625	402
Alaska	29	23	27	29	30	31
Arizona	721	752	748	657	781	703
Arkansas	285	283	289	245	338	330
California	4,856	4,764	4,508	4,010	4,399	3,702
Colorado	433	400	463	327	406	387
Connecticut	274	258	213	171	233	188
Delaware	125	92	93	92	81	123
District of Columbia	315	278	248	194	195	190
Florida	4,546	4,352	4,150	3,230	4,072	4,815
Georgia	2,607	2,505	2,408	1,974	2,371	2,351
Hawaii	76	72	63	50	65	47
Idaho	45	36	34	35	54	34

	2017	2018	2019	2020 (COVID-19 pandemic) <sup>a</sup>	2021	2022 (preliminary) <sup>b</sup>
Area of residence	No.	No.	No.	No.	No.	No.
Illinois	1,382	1,379	1,281	1,081	1,195	998
Indiana	514	514	484	430	528	557
Iowa	125	114	101	100	124	117
Kansas	119	155	132	140	154	124
Kentucky	368	377	326	300	390	376
Louisiana	987	954	879	718	899	872
Maine	29	31	30	16	31	33
Maryland	1,014	994	914	709	749	679
Massachusetts	600	645	537	430	440	268
Michigan	771	718	675	517	633	597
Minnesota	278	288	276	230	297	251
Mississippi	431	475	469	404	419	362
Missouri	505	449	488	369	549	484
Montana	29	24	25	14	22	10
Nebraska	87	77	80	73	105	84
Nevada	497	498	517	397	501	502
New Hampshire	32	38	31	32	32	28
New Jersey	1,110	1,015	1,084	799	1,143	882
New Mexico	148	155	176	129	149	73
New York	2,741	2,454	2,345	1,975	2,116	1,936
North Carolina	1,289	1,180	1,367	1,079	1,390	1,274
North Dakota	39	35	40	37	37	5
Ohio	980	977	965	882	909	772
Oklahoma	302	278	346	342	387	267
Oregon	203	227	198	179	202	234
Pennsylvania	1,097	1,018	994	753	913	834
Rhode Island	85	75	72	52	68	48
South Carolina	704	726	721	660	652	596
South Dakota	41	29	34	34	31	32
Tennessee	720	740	768	646	831	798
Texas	4,363	4,429	4,350	3,596	4,363	3,589
Utah	116	121	135	133	133	126
Vermont	20	18	11	13	12	4
Virginia	864	863	832	618	792	800
Washington	433	497	480	417	461	525
West Virginia	78	93	155	140	149	133
Wisconsin	258	206	211	213	253	263
Wyoming	10	12	13	14	7	10
<b>Subtotal</b>	<b>38,328</b>	<b>37,299</b>	<b>36,421</b>	<b>30,275</b>	<b>35,716</b>	<b>32,846</b>
<b>U.S. dependent areas</b>						
American Samoa	0	0	0	0	0	0
Guam	6	7	11	1	0	0
Northern Mariana Islands	1	1	2	0	0	0
Puerto Rico	447	437	396	300	410	328
Republic of Palau	0	0	0	0	0	0

	2017	2018	2019	2020 (COVID-19 pandemic) <sup>a</sup>	2021	2022 (preliminary) <sup>b</sup>
Area of residence	No.	No.	No.	No.	No.	No.
U.S. Virgin Islands	9	18	15	9	10	11
<b>Subtotal</b>	463	463	424	310	420	339
<b>Total</b>	<b>38,791</b>	<b>37,762</b>	<b>36,845</b>	<b>30,585</b>	<b>36,136</b>	<b>33,185</b>

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at the time of diagnosis of HIV infection. Data are for cases reported to CDC through December 2022.

a Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

b Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

**Table 3d. Diagnoses of HIV infection among persons aged  $\geq 13$  years, by area of residence, 2017–2022—Ending the HIV Epidemic Phase I jurisdictions**

	2017	2018	2019	2020 (COVID-19 pandemic) <sup>a</sup>	2021	2022 (preliminary) <sup>b</sup>
	No.	No.	No.	No.	No.	No.
<b>Arizona</b>						
Maricopa County	492	528	507	471	518	472
<b>California</b>						
Alameda County	204	201	219	159	185	193
Los Angeles County	1,749	1,706	1,545	1,403	1,486	1,160
Orange County	314	287	245	264	266	235
Riverside County	275	263	266	237	258	242
Sacramento County	183	178	164	154	175	108
San Bernardino County	257	262	296	265	301	218
San Diego County	415	385	403	328	369	181
San Francisco County	242	238	210	154	185	201
<b>District of Columbia</b>	315	278	248	194	195	190
<b>Florida</b>						
Broward County	671	583	555	424	570	648
Duval County	295	267	279	231	280	292
Hillsborough County	300	284	256	237	294	309
Miami-Dade County	1,140	1,100	1,056	736	937	1,212
Orange County	465	441	442	358	416	452
Palm Beach County	285	272	222	201	273	341
Pinellas County	165	174	179	149	122	141
<b>Georgia</b>						
Cobb County	156	157	178	135	152	151
DeKalb County	369	359	341	264	342	369
Fulton County	618	601	531	474	525	556
Gwinnett County	177	148	208	144	165	141
<b>Illinois</b>						
Cook County	989	989	902	759	843	644
<b>Indiana</b>						
Marion County	226	205	204	169	216	218

	2017	2018	2019	2020 (COVID-19 pandemic) <sup>a</sup>	2021	2022 (preliminary) <sup>b</sup>
	No.	No.	No.	No.	No.	No.
<b>Louisiana</b>						
East Baton Rouge Parish	163	177	155	124	141	127
Orleans Parish	180	176	159	102	145	138
<b>Maryland</b>						
Baltimore City	236	233	196	173	156	133
Montgomery County	162	126	131	79	96	104
Prince George's County	301	305	279	218	229	231
<b>Massachusetts</b>						
Suffolk County	164	147	133	131	132	72
<b>Michigan</b>						
Wayne County	322	300	289	227	256	236
<b>Nevada</b>						
Clark County	449	443	450	346	445	457
<b>New Jersey</b>						
Essex County	309	259	229	200	266	183
Hudson County	160	164	147	127	149	144
<b>New York</b>						
Bronx County	500	460	504	345	416	345
Kings County	635	550	474	443	441	405
New York County	398	374	339	298	317	289
Queens County	434	417	355	322	333	315
<b>North Carolina</b>						
Mecklenburg County	267	237	269	208	278	251
<b>Ohio</b>						
Cuyahoga County	148	151	159	183	164	124
Franklin County	223	194	215	206	187	146
Hamilton County	187	183	172	132	122	85
<b>Pennsylvania</b>						
Philadelphia County	509	439	445	305	360	307
<b>Puerto Rico</b>						
San Juan Municipio	112	104	89	77	99	95
<b>Tennessee</b>						
Shelby County	259	290	260	234	294	320
<b>Texas</b>						
Bexar County	348	322	332	285	328	260
Dallas County	824	800	747	663	798	769
Harris County	1,103	1,207	1,222	934	1,161	1,102
Tarrant County	303	280	314	294	302	277
Travis County	212	189	178	164	225	209
<b>Washington</b>						
King County	212	287	242	199	218	285

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at the time of diagnosis of HIV infection. Data are for cases reported to CDC through December 2022.

<sup>a</sup> Data for the year 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on HIV access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.

<sup>b</sup> Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

**Table 4a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged  $\geq 13$  years, by selected characteristics, January 2021–September 2022—47 states and the District of Columbia**

	2021					2022 (January-September, <i>preliminary</i> ) <sup>a</sup>				
	Total diagnoses	$\geq 1$ CD4 or VL tests		No CD4 or VL test		Total diagnoses	$\geq 1$ CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	No.	No.	%	No.	%
<b>Gender</b>										
Male	26,654	21,833	81.9	4,821	18.1	20,566	17,079	83.0	3,487	17.0
Female	6,069	4,961	81.7	1,108	18.3	4,707	3,835	81.5	872	18.5
Transgender woman <sup>b</sup>	785	654	83.3	131	16.7	535	452	84.5	83	15.5
Transgender man <sup>b</sup>	55	51	92.7	4	7.3	32	31	96.9	1	3.1
Additional gender identity <sup>c</sup>	43	36	83.7	7	16.3	39	38	97.4	1	2.6
<b>Age at diagnosis (yr)</b>										
13-24	6,561	5,263	80.2	1,298	19.8	4,810	3,953	82.2	857	17.8
25-34	12,337	10,074	81.7	2,263	18.3	9,609	7,959	82.8	1,650	17.2
35-44	7,087	5,824	82.2	1,263	17.8	5,727	4,772	83.3	955	16.7
45-54	4,153	3,462	83.4	691	16.6	3,142	2,597	82.7	545	17.3
>55	3,468	2,912	84.0	556	16.0	2,591	2,154	83.1	437	16.9
<b>Race/ethnicity</b>										
American Indian/Alaska Native	220	182	82.7	38	17.3	156	122	78.2	34	21.8
Asian	699	608	87.0	91	13.0	571	510	89.3	61	10.7
Black/African American	13,650	10,889	79.8	2,761	20.2	10,422	8,316	79.8	2,106	20.2
Hispanic/Latino <sup>d</sup>	9,416	7,958	84.5	1,458	15.5	7,730	6,695	86.6	1,035	13.4
Native Hawaiian/other Pacific Islander	74	59	79.7	15	20.3	61	47	77.0	14	23.0
White	8,580	7,048	82.1	1,532	17.9	6,409	5,310	82.9	1,099	17.1
Multiracial	967	791	81.8	176	18.2	530	435	82.1	95	17.9
<b>Transmission category<sup>e</sup></b>										
Male-to-male sexual contact <sup>f</sup>	22,659	18,717	82.6	3,942	17.4	17,730	14,833	83.7	2,898	16.3
Injection drug use <sup>g</sup>	2,326	1,757	75.5	569	24.5	1,715	1,327	77.4	388	22.6
Male	1,311	975	74.3	337	25.7	928	710	76.6	217	23.4
Female	1,015	783	77.1	232	22.9	787	617	78.4	170	21.6
Male-to-male sexual contact <sup>f</sup> and injection drug use <sup>g</sup>	1,301	1,026	78.8	276	21.2	866	705	81.4	161	18.6
Heterosexual contact <sup>h</sup>	7,244	5,972	82.4	1,272	17.6	5,491	4,505	82.0	986	18.0
Male	2,178	1,779	81.7	399	18.3	1,588	1,298	81.7	290	18.3
Female	5,065	4,192	82.8	873	17.2	3,903	3,207	82.2	696	17.8
<b>Total<sup>i</sup></b>	<b>33,606</b>	<b>27,535</b>	<b>81.9</b>	<b>6,071</b>	<b>18.1</b>	<b>25,879</b>	<b>21,435</b>	<b>82.8</b>	<b>4,444</b>	<b>17.2</b>

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of  $\geq 1$  CD4 or VL tests  $\leq 1$  month after diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

<sup>a</sup> Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

<sup>b</sup> "Transgender woman" includes individuals who were assigned "male" sex at birth but have ever identified as "female" gender.

"Transgender man" includes individuals who were assigned "female" sex at birth but have ever identified as "male" gender

<sup>c</sup> Additional gender identity examples include "bigender," "gender queer," and "two-spirit."

<sup>d</sup> Hispanic/Latino persons can be of any race

<sup>e</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total

<sup>f</sup> Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>g</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>h</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>i</sup> Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

**Table 4b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged  $\geq 13$  years, by area of residence, January 2021–September 2022—47 states and the District of Columbia**

Area of residence	2021					2022 (January-September, <i>preliminary</i> ) <sup>a</sup>				
	Total diagnoses	$\geq 1$ CD4 or VL tests		No CD4 or VL test		Total diagnoses	$\geq 1$ CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	No.	No.	%	No.	%
Alabama	625	502	80.3	123	19.7	359	296	82.5	63	17.5
Alaska	30	28	93.3	2	6.7	19	18	94.7	1	5.3
Arizona	781	661	84.6	120	15.4	671	568	84.6	103	15.4
Arkansas	338	261	77.2	77	22.8	243	194	79.8	49	20.2
California	4,399	3,628	82.5	771	17.5	3,214	2,667	83.0	547	17.0
Colorado	406	343	84.5	63	15.5	325	268	82.5	57	17.5
Connecticut	233	204	87.6	29	12.4	169	143	84.6	26	15.4
Delaware	81	68	84.0	13	16.0	92	78	84.8	14	15.2
District of Columbia	195	154	79.0	41	21.0	171	146	85.4	25	14.6
Florida	4,072	3,366	82.7	706	17.3	3,732	3,147	84.3	585	15.7
Georgia	2,371	1,934	81.6	437	18.4	1,946	1,632	83.9	314	16.1
Hawaii	65	55	84.6	10	15.4	38	32	84.2	6	15.8
Illinois	1,195	1,022	85.5	173	14.5	872	752	86.2	120	13.8
Indiana	528	401	75.9	127	24.1	455	350	76.9	105	23.1
Iowa	124	106	85.5	18	14.5	79	72	91.1	7	8.9
Kansas	154	139	90.3	15	9.7	99	92	92.9	7	7.1
Kentucky	390	289	74.1	101	25.9	300	238	79.3	62	20.7
Louisiana	899	725	80.6	174	19.4	674	529	78.5	145	21.5
Maine	31	27	87.1	4	12.9	28	27	96.4	1	3.6
Maryland	749	650	86.8	99	13.2	566	511	90.3	55	9.7
Massachusetts	440	403	91.6	37	8.4	248	220	88.7	28	11.3
Michigan	633	547	86.4	86	13.6	474	413	87.1	61	12.9
Minnesota	297	254	85.5	43	14.5	193	160	82.9	33	17.1

Area of residence	2021					2022 (January-September, <i>preliminary</i> ) <sup>a</sup>				
	Total diagnoses	≥ 1 CD4 or VL tests		No CD4 or VL test		Total diagnoses	≥ 1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	No.	No.	%	No.	%
Mississippi	419	299	71.4	120	28.6	293	160	54.6	133	45.4
Missouri	549	427	77.8	122	22.2	391	321	82.1	70	17.9
Montana	22	21	95.5	1	4.5	10	7	70.0	3	30.0
Nebraska	105	88	83.8	17	16.2	71	62	87.3	9	12.7
Nevada	501	439	87.6	62	12.4	405	366	90.4	39	9.6
New Hampshire	32	32	100	0	0.0	24	17	70.8	7	29.2
New Mexico	149	127	85.2	22	14.8	67	60	89.6	7	10.4
New York	2,116	1,814	85.7	302	14.3	1,628	1,423	87.4	205	12.6
North Carolina	1,390	1,115	80.2	275	19.8	1,047	849	81.1	198	18.9
North Dakota	37	31	83.8	6	16.2	5	3	60.0	2	40.0
Ohio	909	757	83.3	152	16.7	668	560	83.8	108	16.2
Oklahoma	387	303	78.3	84	21.7	223	175	78.5	48	21.5
Oregon	202	159	78.7	43	21.3	191	163	85.3	28	14.7
Rhode Island	68	58	85.3	10	14.7	44	42	95.5	2	4.5
South Carolina	652	557	85.4	95	14.6	531	434	81.7	97	18.3
South Dakota	31	25	80.6	6	19.4	29	19	65.5	10	34.5
Tennessee	831	583	70.2	248	29.8	656	473	72.1	183	27.9
Texas	4,363	3,431	78.6	932	21.4	3,142	2,519	80.2	623	19.8
Utah	133	111	83.5	22	16.5	110	89	80.9	21	19.1
Vermont	12	12	100	0	0.0	4	3	75.0	1	25.0
Virginia	792	633	79.9	159	20.1	642	523	81.5	119	18.5
Washington	461	407	88.3	54	11.7	393	343	87.3	50	12.7
West Virginia	149	107	71.8	42	28.2	118	72	61.0	46	39.0
Wisconsin	253	226	89.3	27	10.7	211	191	90.5	20	9.5
Wyoming	7	6	85.7	1	14.3	9	8	88.9	1	11.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of  $\geq 1$  CD4 or VL tests  $\leq 1$  month after diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

<sup>a</sup> Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

**Table 4c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged  $\geq 13$  years, by area of residence, January 2021–September 2022—Ending the HIV Epidemic Phase I jurisdictions**

Area of residence	2021					2022 (January-September, <i>preliminary</i> ) <sup>a</sup>				
	Total diagnoses	≥ 1 CD4 or VL tests		No CD4 or VL test		Total diagnoses	≥ 1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	No.	No.	%	No.	%
<b>Arizona</b>										
Maricopa County	518	446	86.1	72	13.9	447	387	86.6	60	13.4

Area of residence	2021					2022 (January-September, <i>preliminary</i> ) <sup>a</sup>				
	Total diagnoses	≥ 1 CD4 or VL tests		No CD4 or VL test		Total diagnoses	≥ 1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	No.	No.	%	No.	%
<b>California</b>										
Alameda County	185	162	87.6	23	12.4	151	130	86.1	21	13.9
Los Angeles County	1,486	1,194	80.3	292	19.7	995	817	82.1	178	17.9
Orange County	266	230	86.5	36	13.5	184	154	83.7	30	16.3
Riverside County	258	199	77.1	59	22.9	221	178	80.5	43	19.5
Sacramento County	175	151	86.3	24	13.7	107	96	89.7	11	10.3
San Bernardino County	301	230	76.4	71	23.6	204	147	72.1	57	27.9
San Diego County	369	307	83.2	62	16.8	172	140	81.4	32	18.6
San Francisco County	185	174	94.1	11	5.9	163	148	90.8	15	9.2
<b>District of Columbia</b>	195	154	79.0	41	21.0	171	146	85.4	25	14.6
<b>Florida</b>										
Broward County	570	467	81.9	103	18.1	492	418	85.0	74	15.0
Duval County	280	222	79.3	58	20.7	220	164	74.5	56	25.5
Hillsborough County	294	234	79.6	60	20.4	244	206	84.4	38	15.6
Miami-Dade County	937	768	82.0	169	18.0	927	778	83.9	149	16.1
Orange County	416	340	81.7	76	18.3	372	303	81.5	69	18.5
Palm Beach County	273	231	84.6	42	15.4	269	243	90.3	26	9.7
Pinellas County	122	99	81.1	23	18.9	97	81	83.5	16	16.5
<b>Georgia</b>										
Cobb County	152	131	86.2	21	13.8	130	111	85.4	19	14.6
DeKalb County	342	283	82.7	59	17.3	296	245	82.8	51	17.2
Fulton County	525	438	83.4	87	16.6	463	394	85.1	69	14.9
Gwinnett County	165	144	87.3	21	12.7	127	114	89.8	13	10.2
<b>Illinois</b>										
Cook County	843	730	86.6	113	13.4	572	497	86.9	75	13.1
<b>Indiana</b>										
Marion County	216	170	78.7	46	21.3	187	141	75.4	46	24.6
<b>Louisiana</b>										
East Baton Rouge Parish	141	112	79.4	29	20.6	91	75	82.4	16	17.6
Orleans Parish	145	131	90.3	14	9.7	100	86	86.0	14	14.0
<b>Maryland</b>										
Baltimore City	156	133	85.3	23	14.7	116	107	92.2	9	7.8
Montgomery County	96	85	88.5	11	11.5	84	76	90.5	8	9.5
Prince George's County	229	198	86.5	31	13.5	185	168	90.8	17	9.2
<b>Massachusetts</b>										
Suffolk County	132	127	96.2	5	3.8	68	61	89.7	7	10.3
<b>Michigan</b>										
Wayne County	256	216	84.4	40	15.6	191	161	84.3	30	15.7
<b>Nevada</b>										
Clark County	445	387	87.0	58	13.0	369	333	90.2	36	9.8
<b>New York</b>										
Bronx County	416	359	86.3	57	13.7	296	250	84.5	46	15.5
Kings County	441	378	85.7	63	14.3	345	312	90.4	33	9.6
New York County	317	262	82.6	55	17.4	252	210	83.3	42	16.7

Area of residence	2021					2022 (January-September, <i>preliminary</i> ) <sup>a</sup>				
	Total diagnoses	≥ 1 CD4 or VL tests		No CD4 or VL test		Total diagnoses	≥ 1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	No.	No.	%	No.	%
Queens County	333	285	85.6	48	14.4	260	233	89.6	27	10.4
<b>North Carolina</b>										
Mecklenburg County	278	226	81.3	52	18.7	214	167	78.0	47	22.0
<b>Ohio</b>										
Cuyahoga County	164	146	89.0	18	11.0	100	86	86.0	14	14.0
Franklin County	187	161	86.1	26	13.9	144	125	86.8	19	13.2
Hamilton County	122	109	89.3	13	10.7	74	66	89.2	8	10.8
<b>Pennsylvania</b>										
Philadelphia County	360	301	83.6	59	16.4	248	204	82.3	44	17.7
<b>Tennessee</b>										
Shelby County	294	177	60.2	117	39.8	268	172	64.2	96	35.8
<b>Texas</b>										
Bexar County	328	263	80.2	65	19.8	254	205	80.7	49	19.3
Dallas County	798	613	76.8	185	23.2	660	516	78.2	144	21.8
Harris County	1,161	873	75.2	288	24.8	954	757	79.4	197	20.6
Tarrant County	302	236	78.1	66	21.9	250	181	72.4	69	27.6
Travis County	225	195	86.7	30	13.3	174	152	87.4	22	12.6
<b>Washington</b>										
King County	218	194	89.0	24	11.0	212	187	88.2	25	11.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of  $\geq 1$  CD4 or VL tests  $\leq 1$  month after diagnosis of HIV infection. Data are based on residence at time of diagnosis of HIV infection. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

<sup>a</sup> Data for the year 2022 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

**Table 5a. HIV viral suppression during 2021 among persons aged  $\geq 13$  years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by selected characteristics—47 states and the District of Columbia**

	Persons alive at year-end 2021		VL < 200 copies/mL	
	No.		No.	%
<b>Gender</b>				
Male		733,871	486,719	66.3
Female		217,656	140,231	64.4
Transgender woman <sup>a</sup>		11,674	7,757	66.4
Transgender man <sup>a</sup>		499	370	74.1
Additional gender identity <sup>b</sup>		302	223	73.8
<b>Age at year-end 2020 (yr)</b>				
13–24		27,140	17,677	65.1
25–34		152,935	97,532	63.8

	Persons alive at year-end 2021		VL < 200 copies/mL	
	No.	No.	%	
35–44	183,689	117,369	63.9	
45–54	233,009	154,813	66.4	
≥ 55	367,229	247,909	67.5	
<b>Race/ethnicity</b>				
American Indian/Alaska Native	2,992	1,908	63.8	
Asian <sup>c</sup>	15,188	10,614	69.9	
Black/African American	386,688	238,353	61.6	
Hispanic/Latino <sup>d</sup>	227,387	146,163	64.3	
Native Hawaiian/other Pacific Islander	855	542	63.4	
White	280,199	200,892	71.7	
Multiracial	50,067	36,786	73.5	
<b>Transmission category<sup>e</sup></b>				
Male-to-male sexual contact <sup>f</sup>	561,493	385,253	68.6	
Injection drug use <sup>g</sup>	96,246	53,923	56.0	
Male	54,849	28,778	52.5	
Female	41,397	25,145	60.7	
Male-to-male sexual contact <sup>f</sup> and injection drug use <sup>g</sup>	53,043	34,514	65.1	
Heterosexual contact <sup>h</sup>	239,228	153,516	64.2	
Male	69,386	42,133	60.7	
Female	169,842	111,383	65.6	
Other <sup>i</sup>	13,992	8,094	57.8	
Male	7,039	3,996	56.8	
Female	6,953	4,098	58.9	
<b>Total<sup>j</sup></b>	<b>964,002</b>	<b>635,300</b>	<b>65.9</b>	

Abbreviations: VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage [footnotes only].

Note. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. A VL test result of < 200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

<sup>a</sup> “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender.

“Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.

<sup>b</sup> Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

<sup>c</sup> Includes Asian/Pacific Islander legacy cases.

<sup>d</sup> Hispanic/Latino persons can be of any race.

<sup>e</sup> Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.


<sup>f</sup> Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).

<sup>g</sup> Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

<sup>h</sup> Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.

<sup>i</sup> Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

<sup>j</sup> Includes 626 persons of unknown race/ethnicity.

**Table 5b. HIV viral suppression during 2021 among persons aged  $\geq 13$  years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by area of residence—47 states and the District of Columbia** 

	Persons alive at year-end 2021		VL < 200 copies/mL	
	No.		No.	%
Alabama	13,774		8,146	59.1
Alaska	718		572	79.7
Arizona	17,490		10,955	62.6
Arkansas	5,900		3,097	52.5
California	131,709		87,675	66.6
Colorado	13,022		7,890	60.6
Connecticut	10,406		7,484	71.9
Delaware	3,439		2,525	73.4
District of Columbia	13,401		7,418	55.4
Florida	113,218		77,793	68.7
Georgia	57,083		35,470	62.1
Hawaii	2,323		1,839	79.2
Illinois	34,556		21,881	63.3
Indiana	11,821		8,322	70.4
Iowa	2,923		2,389	81.7
Kansas	3,340		2,523	75.5
Kentucky	7,759		5,062	65.2
Louisiana	20,700		14,263	68.9
Maine	1,650		1,279	77.5
Maryland	32,719		20,214	61.8
Massachusetts	20,672		14,483	70.1
Michigan	16,652		11,987	72.0
Minnesota	8,915		5,962	66.9
Mississippi <sup>a</sup>	9,474		5,646	59.6
Missouri	12,570		8,403	66.8
Montana	698		564	80.8
Nebraska	2,274		1,541	67.8
Nevada	10,921		6,971	63.8
New Hampshire	1,333		1,006	75.5
New Mexico	3,873		2,183	56.4
New York	122,351		79,119	64.7
North Carolina	32,933		22,383	68.0
North Dakota	506		317	62.6
Ohio	23,181		15,307	66.0
Oklahoma	6,585		4,046	61.4
Oregon	7,268		5,616	77.3
Rhode Island	2,647		1,809	68.3
South Carolina	17,474		12,679	72.6
South Dakota	687		380	55.3
Tennessee	17,938		12,005	66.9

	Persons alive at year-end 2021		VL < 200 copies/mL	
	No.		No.	%
Texas		96,292	60,494	62.8
Utah		3,317	2,338	70.5
Vermont		712	531	74.6
Virginia		23,635	15,378	65.1
Washington		14,141	11,121	78.6
West Virginia		2,056	1,118	54.4
Wisconsin		6,579	4,869	74.0
Wyoming		367	247	67.3
<b>Total</b>		<b>964,002</b>	<b>635,300</b>	<b>65.9</b>

Abbreviations: VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage [footnotes only].

Note. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. A VL test result of < 200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

<sup>a</sup> Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2021.

**Table 5c. HIV viral suppression during 2021 among persons aged  $\geq$  13 years with HIV infection diagnosed by year-end 2020 and alive at year-end 2021, by area of residence — Ending the HIV Epidemic Phase I jurisdictions**

Area of residence	Persons alive at year-end 2021		VL < 200 copies/mL	
	No.		No.	%
<b>Arizona</b>				
Maricopa County		11,910	7,494	63.0
<b>California</b>				
Alameda County		5,808	4,152	71.5
Los Angeles County		49,007	31,877	65.0
Orange County		6,963	4,557	65.4
Riverside County		9,862	7,691	78.0
Sacramento County		4,467	3,128	70.0
San Bernardino County		4,769	2,919	61.2
San Diego County		13,163	7,748	58.9
San Francisco County		11,437	8,350	73.0
<b>District of Columbia</b>		13,401	7,418	55.3
<b>Florida</b>				
Broward County		19,788	13,586	68.7
Duval County		6,218	4,324	69.5
Hillsborough County		7,162	5,196	72.7
Miami-Dade County		26,224	16,142	61.5
Orange County		8,938	6,433	72.0
Palm Beach County		7,887	5,100	64.7
Pinellas County		4,812	3,745	77.8

Area of residence	Persons alive at year-end 2021		VL < 200 copies/mL	
	No.	No.	%	
<b>Georgia</b>				
Cobb County	3,501	2,332	66	
DeKalb County	8,802	5,637	64	
Fulton County	15,851	9,885	62	
Gwinnett County	3,199	2,147	67	
<b>Illinois</b>				
Cook County	24,919	15,173	61	
<b>Indiana</b>				
Marion County	4,752	3,507	74	
<b>Louisiana</b>				
East Baton Rouge Parish	3,983	3,021	76	
Orleans Parish	4,721	3,199	68	
<b>Maryland</b>				
Baltimore City	10,110	6,303	62	
Montgomery County	3,850	2,028	53	
Prince George's County	7,865	4,763	61	
<b>Massachusetts</b>				
Suffolk County	5,527	3,765	68	
<b>Michigan</b>				
Wayne County	6,974	4,767	68	
<b>Nevada</b>				
Clark County	9,255	5,909	64	
<b>New York</b>				
Bronx County	26,854	17,245	64	
Kings County	25,601	16,330	64	
New York County	25,777	15,598	60	
Queens County	15,810	10,089	64	
<b>North Carolina</b>				
Mecklenburg County	6,013	4,025	67	
<b>Ohio</b>				
Cuyahoga County	4,810	3,132	65	
Franklin County	5,072	3,581	71	
Hamilton County	3,037	1,954	64	
<b>Pennsylvania</b>				
Philadelphia County	16,404	10,051	61	
<b>Tennessee</b>				
Shelby County	6,278	4,007	64	
<b>Texas</b>				
Bexar County	6,596	4,112	62	
Dallas County	18,809	11,348	60	
Harris County	26,727	17,120	64	
Tarrant County	6,120	4,162	68	
Travis County	5,032	3,506	70	
<b>Washington</b>				
King County	6,965	5,707	82	

Abbreviations: VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; CD4, CD4+ T-lymphocyte count (cells/ $\mu$ L) or percentage [footnotes only].

Note. Data are based on address of residence as of December 31, 2021 (i.e., most recent known address). Data for the year 2021 are preliminary and based on death data received by CDC as of December 2022. A VL test result of < 200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2021. Data are not provided for states and associated jurisdictions that do not have laws requiring reporting of all CD4 and viral loads or that have incomplete reporting of laboratory data to CDC. Areas without laws: Idaho. Areas with incomplete reporting: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

**Table 6a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017–September 2022, among persons aged  $\geq$  16 years, by selected characteristics—United States**

	2017			2018			2019		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
<b>Sex at birth</b>									
Male	143,672	993,840	14.5	204,039	989,200	20.6	253,750	989,200	25.7
Female	11,261	227,240	5.0	15,796	227,010	7.0	21,040	227,010	9.3
<b>Age (yr)</b>									
16–24	20,080	259,130	7.7	29,300	246,290	11.9	37,595	246,290	15.3
25–34	62,346	425,690	14.6	90,658	434,680	20.9	111,654	434,680	25.7
35–44	36,475	233,560	15.6	50,699	238,470	21.3	64,030	238,470	26.9
45–54	23,763	180,870	13.1	31,487	173,420	18.2	37,396	173,420	21.6
$\geq$ 55	12,308	121,830	10.1	17,715	123,350	14.4	24,159	123,350	19.6
<b>Race/ethnicity<sup>d</sup></b>									
Black/African American	19,776	475,100	4.2	29,059	468,540	6.2	37,447	468,540	8.0
Hispanic/Latino <sup>e</sup>	23,416	299,580	7.8	35,110	312,820	11.2	45,212	312,820	14.5
Other	7,020	132,040	5.3	9,890	131,180	7.5	12,289	131,180	9.4
White	104,820	311,250	33.7	145,894	300,650	48.5	179,985	300,650	59.9
<b>Total</b>	<b>155,032</b>	<b>1,221,080</b>	<b>12.7</b>	<b>219,954</b>	<b>1,216,210</b>	<b>18.1</b>	<b>274,933</b>	<b>1,216,210</b>	<b>22.6</b>

	2020 (COVID-19 pandemic)			2021			2022 (January – September)		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
<b>Sex at birth</b>									
Male	276,915	989,200	28.0	337,697	989,200	34.1	355,379	989,200	35.9
Female	23,562	227,010	10.4	28,014	227,010	12.3	26,888	227,010	11.8
<b>Age (yr)</b>									
16–24	37,709	246,290	15.3	48,552	246,290	19.7	46,933	246,290	19.1
25–34	120,220	434,680	27.7	145,758	434,680	33.5	151,005	434,680	34.7
35–44	71,840	238,470	30.1	88,516	238,470	37.1	96,302	238,470	40.4
45–54	40,454	173,420	23.3	46,224	173,420	26.7	47,616	173,420	27.5
$\geq$ 55	30,208	123,350	24.5	36,740	123,350	29.8	40,283	123,350	32.7
<b>Race/ethnicity<sup>d</sup></b>									

	2020 (COVID-19 pandemic)			2021			2022 (January – September)		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
Black/African American	43,332	468,540	9.2	51,878	468,540	11.1	51,708	468,540	11.0
Hispanic/Latino <sup>e</sup>	51,104	312,820	16.3	64,018	312,820	20.5	66,177	312,820	21.2
Other	12,840	131,180	9.8	15,779	131,180	12.0	16,779	131,180	12.8
White	193,268	300,650	64.3	234,318	300,650	77.9	247,701	300,650	82.4
<b>Total</b>	<b>300,544</b>	<b>1,216,210</b>	<b>24.7</b>	<b>365,994</b>	<b>1,216,210</b>	<b>30.1</b>	<b>382,364</b>	<b>1,216,210</b>	<b>31.4</b>

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

<sup>a</sup> Estimated by using data from IQVIA pharmacy database reported through September 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported; thus, values may not sum to column total.

<sup>b</sup> Estimated by using 2017 and 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018–2022 PrEP coverage data.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

<sup>d</sup> Race/ethnicity data were only available for <40% of persons prescribed PrEP each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.

<sup>e</sup> Hispanic/Latino persons can be of any race.

**Table 6b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2022, among persons aged ≥16 years, by area of residence—United States and Puerto Rico**

	2017			2018			2019		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
Alabama	1,010	11,390	8.9	1,531	11,020	13.9	1,834	11,020	16.6
Alaska	125	2,370	5.3	199	1,780	11.2	227	1,780	12.8
Arizona	2,250	26,820	8.4	3,494	25,780	13.6	4,575	25,780	17.7
Arkansas	412	4,840	8.5	585	5,130	11.4	728	5,130	14.2
California	26,071	166,150	15.7	35,902	165,030	21.8	41,579	165,030	25.2
Colorado	2,410	25,510	9.4	3,449	25,120	13.7	4,396	25,120	17.5
Connecticut	1,574	10,970	14.3	2,268	9,560	23.7	2,661	9,560	27.8
Delaware	280	4,860	5.8	423	4,400	9.6	476	4,400	10.8
District of Columbia	3,800	13,710	27.7	5,007	12,950	38.7	5,882	12,950	45.4
Florida	8,493	125,160	6.8	14,715	125,330	11.7	21,744	125,330	17.3
Georgia	4,462	40,680	11.0	6,295	39,030	16.1	8,645	39,030	22.1
Hawaii	438	5,440	8.1	679	4,360	15.6	815	4,360	18.7
Idaho	265	3,860	6.9	370	4,790	7.7	479	4,790	10.0

	2017			2018			2019		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
Illinois	10,133	54,620	18.6	13,858	55,860	24.8	16,641	55,860	29.8
Indiana	1,553	21,640	7.2	2,195	22,170	9.9	2,979	22,170	13.4
Iowa	764	4,280	17.9	1,145	4,760	24.1	1,414	4,760	29.7
Kansas	523	5,570	9.4	722	5,060	14.3	902	5,060	17.8
Kentucky	750	13,170	5.7	1,205	12,990	9.3	1,600	12,990	12.3
Louisiana	2,190	15,490	14.1	3,302	15,920	20.7	3,916	15,920	24.6
Maine	318	3,270	9.7	499	3,950	12.6	651	3,950	16.5
Maryland	2,677	28,150	9.5	3,944	27,300	14.4	4,929	27,300	18.1
Massachusetts	5,503	25,110	21.9	7,615	24,900	30.6	9,303	24,900	37.4
Michigan	2,254	28,520	7.9	3,471	29,570	11.7	4,349	29,570	14.7
Minnesota	2,506	23,770	10.5	3,469	21,720	16.0	4,202	21,720	19.3
Mississippi	471	5,030	9.4	653	4,530	14.4	948	4,530	20.9
Missouri	1,882	19,420	9.7	2,720	18,370	14.8	3,474	18,370	18.9
Montana	119	2,750	4.3	185	2,290	8.1	268	2,290	11.7
Nebraska	346	2,590	13.4	471	2,180	21.6	619	2,180	28.4
Nevada	1,049	10,870	9.7	1,485	11,390	13.0	2,181	11,390	19.1
New Hampshire	319	3,110	10.3	498	3,020	16.5	618	3,020	20.5
New Jersey	3,273	28,590	11.4	4,587	25,280	18.1	5,667	25,280	22.4
New Mexico	612	6,720	9.1	810	6,800	11.9	1,072	6,800	15.8
New York	22,484	74,450	30.2	30,023	72,640	41.3	35,281	72,640	48.6
North Carolina	2,584	33,110	7.8	4,019	32,490	12.4	5,397	32,490	16.6
North Dakota	108	1,230	8.8	160	1,520	10.5	187	1,520	12.3
Ohio	3,470	40,940	8.5	4,735	40,320	11.7	6,095	40,320	15.1
Oklahoma	529	11,030	4.8	810	11,030	7.3	1,155	11,030	10.5
Oregon	2,048	20,720	9.9	2,763	19,750	14.0	3,400	19,750	17.2
Pennsylvania	6,085	36,160	16.8	8,502	36,490	23.3	10,092	36,490	27.7
Puerto Rico <sup>d</sup>	123	9,700	1.3	246	9,700	2.5	329	9,700	3.4
Rhode Island	625	4,360	14.3	862	3,880	22.2	1,082	3,880	27.9
South Carolina	703	10,390	6.8	1,241	10,390	11.9	1,724	10,390	16.6
South Dakota	55	1,000	5.5	101	910	11.1	150	910	16.5
Tennessee	1,709	22,890	7.5	2,596	22,460	11.6	3,892	22,460	17.3
Texas	11,084	123,400	9.0	17,702	123,790	14.3	23,120	123,790	18.7
Utah	1,050	6,900	15.2	1,490	6,840	21.8	2,035	6,840	29.8
Vermont	217	1,490	14.6	280	1,060	26.4	337	1,060	31.8
Virginia	2,043	33,670	6.1	3,121	31,430	9.9	4,403	31,430	14.0
Washington	6,332	35,600	17.8	8,238	40,050	20.6	9,885	40,050	24.7
West Virginia	237	3,660	6.5	369	5,250	7.0	570	5,250	10.9
Wisconsin	1,289	14,230	9.1	1,856	12,980	14.3	2,471	12,980	19.0
Wyoming	49	1,410	3.5	73	890	8.2	96	890	10.8

	2020 (COVID-19 pandemic)			2021			2022 (January – September)		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
Alabama	1,908	11,020	17.3	2,764	11,020	25.1	3,018	11,020	27.4
Alaska	243	1,780	13.7	308	1,780	17.3	347	1,780	19.5
Arizona	5,055	25,780	19.6	6,571	25,780	25.5	7,297	25,780	28.3
Arkansas	861	5,130	16.8	1,275	5,130	24.9	1,449	5,130	28.2
California	42,234	165,030	25.6	50,239	165,030	30.4	53,925	165,030	32.7
Colorado	4,791	25,120	19.1	6,187	25,120	24.6	6,625	25,120	26.4
Connecticut	2,459	9,560	25.7	3,036	9,560	31.8	3,473	9,560	36.3
Delaware	474	4,400	10.8	645	4,400	14.7	733	4,400	16.7
District of Columbia	5,967	12,950	46.1	6,790	12,950	52.4	6,945	12,950	53.6
Florida	34,501	125,330	27.5	42,584	125,330	34.0	39,596	125,330	31.6
Georgia	9,754	39,030	25.0	12,173	39,030	31.2	12,271	39,030	31.4
Hawaii	902	4,360	20.7	1,134	4,360	26.0	1,308	4,360	30.0
Idaho	666	4,790	13.9	878	4,790	18.3	933	4,790	19.5
Illinois	15,962	55,860	28.6	18,417	55,860	33.0	19,543	55,860	35.0
Indiana	3,195	22,170	14.4	4,261	22,170	19.2	4,801	22,170	21.7
Iowa	1,555	4,760	32.7	1,951	4,760	41.0	1,945	4,760	40.9
Kansas	951	5,060	18.8	1,278	5,060	25.3	1,383	5,060	27.3
Kentucky	1,654	12,990	12.7	2,225	12,990	17.1	2,576	12,990	19.8
Louisiana	3,566	15,920	22.4	4,152	15,920	26.1	4,156	15,920	26.1
Maine	669	3,950	16.9	908	3,950	23.0	977	3,950	24.7
Maryland	4,797	27,300	17.6	5,793	27,300	21.2	5,981	27,300	21.9
Massachusetts	9,369	24,900	37.6	10,164	24,900	40.8	11,348	24,900	45.6
Michigan	4,665	29,570	15.8	5,900	29,570	20.0	6,261	29,570	21.2
Minnesota	4,206	21,720	19.4	5,251	21,720	24.2	5,817	21,720	26.8
Mississippi	1,091	4,530	24.1	1,592	4,530	35.1	1,525	4,530	33.7
Missouri	3,564	18,370	19.4	4,173	18,370	22.7	4,484	18,370	24.4
Montana	294	2,290	12.8	395	2,290	17.2	457	2,290	20.0
Nebraska	718	2,180	32.9	1,004	2,180	46.1	1,128	2,180	51.7
Nevada	2,497	11,390	21.9	4,877	11,390	42.8	4,422	11,390	38.8
New Hampshire	650	3,020	21.5	803	3,020	26.6	886	3,020	29.3
New Jersey	5,904	25,280	23.4	7,267	25,280	28.7	7,725	25,280	30.6
New Mexico	1,235	6,800	18.2	1,594	6,800	23.4	1,767	6,800	26.0
New York	34,116	72,640	47.0	39,082	72,640	53.8	40,223	72,640	55.4
North Carolina	6,161	32,490	19.0	7,964	32,490	24.5	8,697	32,490	26.8
North Dakota	183	1,520	12.0	246	1,520	16.2	295	1,520	19.4
Ohio	6,802	40,320	16.9	8,465	40,320	21.0	9,071	40,320	22.5
Oklahoma	1,523	11,030	13.8	2,321	11,030	21.0	2,423	11,030	22.0
Oregon	3,826	19,750	19.4	4,691	19,750	23.8	5,283	19,750	26.7
Pennsylvania	10,562	36,490	28.9	13,049	36,490	35.8	14,090	36,490	38.6
Puerto Rico <sup>d</sup>	368	9,700	3.8	608	9,700	6.3	698	9,700	7.2
Rhode Island	1,155	3,880	29.8	1,512	3,880	39.0	1,616	3,880	41.6

	2020 (COVID-19 pandemic)			2021			2022 (January – September)		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
South Carolina	2,103	10,390	20.2	2,934	10,390	28.2	3,185	10,390	30.7
South Dakota	141	910	15.5	214	910	23.5	263	910	28.9
Tennessee	5,166	22,460	23.0	7,227	22,460	32.2	7,877	22,460	35.1
Texas	27,496	123,790	22.2	34,728	123,790	28.1	35,883	123,790	29.0
Utah	2,366	6,840	34.6	3,262	6,840	47.7	3,535	6,840	51.7
Vermont	321	1,060	30.3	480	1,060	45.3	501	1,060	47.3
Virginia	5,117	31,430	16.3	6,280	31,430	20.0	6,607	31,430	21.0
Washington	10,065	40,050	25.1	11,377	40,050	28.4	12,134	40,050	30.3
West Virginia	521	5,250	9.9	707	5,250	13.5	785	5,250	15.0
Wisconsin	2,529	12,980	19.5	2,816	12,980	21.7	2,928	12,980	22.6
Wyoming	98	890	11.0	139	890	15.6	160	890	18.0

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

<sup>a</sup> Estimated by using data from IQVIA pharmacy database reported through September 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.

<sup>b</sup> Estimated by using 2017 and 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau's American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018–2022 PrEP coverage data.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

<sup>d</sup> Number of persons with PrEP indications in Puerto Rico is not available in 2017. Number of persons with PrEP indications in 2018 is used for 2017 denominator.

**Table 6c. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage during January 2017 through September 2022, among persons aged ≥16 years, by area of residence—Ending the HIV Epidemic Phase I jurisdictions**

	2017			2018			2019		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
<b>Arizona</b>									
Maricopa County	1,787	23,540	7.6	2,792	22,720	12.3	3,532	22,720	15.5
<b>California</b>									
Alameda County	1,401	7,260	19.3	1,851	8,930	20.7	2,156	8,930	24.1
Los Angeles County	8,656	64,180	13.5	12,077	67,450	17.9	13,679	67,450	20.3
Orange County	1,050	9,990	10.5	1,602	10,510	15.2	2,036	10,510	19.4
Riverside County	993	11,040	9.0	1,419	11,080	12.8	1,797	11,080	16.2

	2017			2018			2019		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
Sacramento County	581	5,460	10.6	787	5,920	13.3	955	5,920	16.1
San Bernardino County	379	12,450	3.0	608	11,890	5.1	751	11,890	6.3
San Diego County	2,340	19,420	12.0	3,360	14,500	23.2	3,729	14,500	25.7
San Francisco County	6,245	11,330	55.1	7,811	10,840	72.1	8,828	10,840	81.4
<i>District of Columbia</i>	3,800	13,710	27.7	5,007	12,950	38.7	5,882	12,950	45.4
<i>Florida</i>									
Broward County	1,975	20,030	9.9	2,906	20,470	14.2	3,837	20,470	18.7
Duval County	243	9,250	2.6	367	8,970	4.1	496	8,970	5.5
Hillsborough County	613	12,670	4.8	1,094	12,910	8.5	1,385	12,910	10.7
Miami-Dade County	1,936	22,190	8.7	3,796	21,760	17.4	6,462	21,760	29.7
Orange County	1,011	16,500	6.1	1,870	15,310	12.2	2,782	15,310	18.2
Palm Beach County	366	7,620	4.8	577	9,170	6.3	883	9,170	9.6
Pinellas County	481	10,470	4.6	820	9,530	8.6	1,139	9,530	12.0
<i>Georgia</i>									
Cobb County	272	3,570	7.6	388	3,070	12.6	569	3,070	18.5
DeKalb County	863	6,370	13.5	1,170	6,290	18.6	1,539	6,290	24.5
Fulton County	1,884	12,060	15.6	2,553	13,120	19.5	3,298	13,120	25.1
Gwinnett County	318	3,390	9.4	458	3,240	14.1	686	3,240	21.2
<i>Illinois</i>									
Cook County	8,490	38,270	22.2	11,420	39,060	29.2	13,619	39,060	34.9
<i>Indiana</i>									
Marion County	688	8,490	8.1	867	9,150	9.5	1,149	9,150	12.6
<i>Louisiana</i>									
East Baton Rouge Parish	223	1,290	17.3	437	1,810	24.1	489	1,810	27.0
Orleans Parish	860	5,230	16.4	1,193	4,590	26.0	1,512	4,590	32.9
<i>Maryland</i>									
Baltimore City	466	6,000	7.8	655	6,330	10.3	900	6,330	14.2
Montgomery County	513	5,790	8.9	765	5,770	13.3	894	5,770	15.5
Prince George's County	439	3,830	11.5	653	4,040	16.2	799	4,040	19.8
<i>Massachusetts</i>									
Suffolk County	1,673	7,050	23.7	2,219	6,520	34.0	2762	6,520	42.4
<i>Michigan</i>									

	2017			2018			2019		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
Wayne County	686	9,470	7.2	1,020	9,270	11.0	1,201	9,270	13.0
<b>Nevada</b>									
Clark County	889	8,790	10.1	1,244	11,670	10.7	1,860	11,670	15.9
<b>New Jersey</b>									
Essex County	393	5,190	7.6	576	4,090	14.1	679	4,090	16.6
Hudson County	629	4,720	13.3	859	4,650	18.5	1,057	4,650	22.7
<b>New York</b>									
Bronx County	1,290	6,690	19.3	1,984	5,570	35.6	2,194	5,570	39.4
Kings County	4,745	15,300	31.0	6,324	15,650	40.4	7,574	15,650	48.4
New York County	9,453	14,790	63.9	12,162	15,540	78.3	14,147	15,540	91.0
Queens County	2,487	8,740	28.5	3,272	9,230	35.4	3,857	9,230	41.8
<b>North Carolina</b>									
Mecklenburg County	654	9,430	6.9	965	8,450	11.4	1,343	8,450	15.9
<b>Ohio</b>									
Cuyahoga County	596	8,200	7.3	811	7,520	10.8	953	7,520	12.7
Franklin County	1,286	13,660	9.4	1,616	11,620	13.9	2,032	11,620	17.5
Hamilton County	259	6,430	4.0	434	7,720	5.6	564	7,720	7.3
<b>Pennsylvania</b>									
Philadelphia County	2,356	8,550	27.6	3,221	9,840	32.7	3,650	9,840	37.1
<b>Puerto Rico</b>									
San Juan Municipiod	16	2,190	0.7	21	2,190	1.0	25	2,190	1.1
<b>Tennessee</b>									
Shelby County	301	7,590	4.0	460	6,450	7.1	633	6,450	9.8
<b>Texas</b>									
Bexar County	665	13,010	5.1	1,142	11,920	9.6	1,530	11,920	12.8
Dallas County	2,119	22,000	9.6	3,230	28,670	11.3	4,095	28,670	14.3
Harris County	2,520	39,780	6.3	3,937	40,670	9.7	4,929	40,670	12.1
Tarrant County	658	11,550	5.7	1,170	11,340	10.3	1,452	11,340	12.8
Travis County	2,176	10,810	20.1	3,346	11,590	28.9	4,527	11,590	39.1
<b>Washington</b>									
King County	4,557	13,690	33.3	5,769	17,890	32.2	6,890	17,890	38.5

	2020 (COVID-19 pandemic)			2021			2022 (January – September)		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
<b>Arizona</b>									

	2020 (COVID-19 pandemic)			2021			2022 (January – September)		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
Maricopa County	3,891	22,720	17.1	5,026	22,720	22.1	5,618	22,720	24.7
<b>California</b>									
Alameda County	2,013	8,930	22.5	2,217	8,930	24.8	2,389	8,930	26.8
Los Angeles County	14,705	67,450	21.8	18,457	67,450	27.4	20,495	67,450	30.4
Orange County	2,195	10,510	20.9	2,832	10,510	26.9	2,917	10,510	27.8
Riverside County	1,933	11,080	17.4	2,538	11,080	22.9	2,809	11,080	25.4
Sacramento County	976	5,920	16.5	1,103	5,920	18.6	1,197	5,920	20.2
San Bernardino County	816	11,890	6.9	1,190	11,890	10.0	1,340	11,890	11.3
San Diego County	3,795	14,500	26.2	4,430	14,500	30.6	4,707	14,500	32.5
San Francisco County	8,133	10,840	75.0	8,189	10,840	75.5	8,116	10,840	74.9
<b>District of Columbia</b>	5,967	12,950	46.1	6,790	12,950	52.4	6,945	12,950	53.6
<b>Florida</b>									
Broward County	6,779	20,470	33.1	8,328	20,470	40.7	7,070	20,470	34.5
Duval County	720	8,970	8.0	883	8,970	9.8	1,188	8,970	13.2
Hillsborough County	1,534	12,910	11.9	2,043	12,910	15.8	2,284	12,910	17.7
Miami-Dade County	10,190	21,760	46.8	11,410	21,760	52.4	9,361	21,760	43.0
Orange County	3,879	15,310	25.3	4,722	15,310	30.8	5,008	15,310	32.7
Palm Beach County	3,008	9,170	32.8	2,760	9,170	30.1	2,073	9,170	22.6
Pinellas County	1,225	9,530	12.9	1,655	9,530	17.4	1,876	9,530	19.7
<b>Georgia</b>									
Cobb County	656	3,070	21.4	812	3,070	26.4	825	3,070	26.9
DeKalb County	1,680	6,290	26.7	2,016	6,290	32.1	2,012	6,290	32.0
Fulton County	3,590	13,120	27.4	4,269	13,120	32.5	4,235	13,120	32.3
Gwinnett County	797	3,240	24.6	1,005	3,240	31.0	1,027	3,240	31.7
<b>Illinois</b>									
Cook County	12,891	39,060	33.0	14,755	39,060	37.8	15,455	39,060	39.6
<b>Indiana</b>									
Marion County	1,209	9,150	13.2	1,591	9,150	17.4	1,788	9,150	19.5
<b>Louisiana</b>									
East Baton Rouge Parish	529	1,810	29.2	584	1,810	32.3	536	1,810	29.6
Orleans Parish	1,328	4,590	28.9	1,517	4,590	33.1	1,486	4,590	32.4

	2020 (COVID-19 pandemic)			2021			2022 (January – September)		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
<b>Maryland</b>									
Baltimore City	841	6,330	13.3	974	6,330	15.4	984	6,330	15.5
Montgomery County	898	5,770	15.6	1,151	5,770	19.9	1,258	5,770	21.8
Prince George's County	819	4,040	20.3	984	4,040	24.4	949	4,040	23.5
<b>Massachusetts</b>									
Suffolk County	2,798	6,520	42.9	2,809	6,520	43.1	3,136	6,520	48.1
<b>Michigan</b>									
Wayne County	1,230	9,270	13.3	1,554	9,270	16.8	1,613	9,270	17.4
<b>Nevada</b>									
Clark County	2,094	11,670	17.9	4,284	11,670	36.7	3,491	11,670	29.9
<b>New Jersey</b>									
Essex County	710	4,090	17.4	836	4,090	20.4	869	4,090	21.2
Hudson County	1,065	4,650	22.9	1,301	4,650	28.0	1,384	4,650	29.8
<b>New York</b>									
Bronx County	2,011	5,570	36.1	2,074	5,570	37.2	1,853	5,570	33.3
Kings County	7,432	15,650	47.5	8,871	15,650	56.7	9,080	15,650	58.0
New York County	13,748	15,540	88.5	15,745	15,540	101.3	16,059	15,540	103.3
Queens County	3,795	9,230	41.1	4,279	9,230	46.4	4,514	9,230	48.9
<b>North Carolina</b>									
Mecklenburg County	1,575	8,450	18.6	1,974	8,450	23.4	2,069	8,450	24.5
<b>Ohio</b>									
Cuyahoga County	963	7,520	12.8	1,261	7,520	16.8	1,445	7,520	19.2
Franklin County	2,301	11,620	19.8	2,731	11,620	23.5	2,793	11,620	24.0
Hamilton County	638	7,720	8.3	815	7,720	10.6	862	7,720	11.2
<b>Pennsylvania</b>									
Philadelphia County	3,500	9,840	35.6	4,049	9,840	41.1	4,345	9,840	44.2
<b>Puerto Rico</b>									
San Juan Municipiod	27	2,190	1.2	62	2,190	2.8	99	2,190	4.5
<b>Tennessee</b>									
Shelby County	812	6,450	12.6	941	6,450	14.6	1,002	6,450	15.5
<b>Texas</b>									
Bexar County	1,783	11,920	15.0	2,355	11,920	19.8	2,508	11,920	21.0
Dallas County	5,152	28,670	18.0	6,544	28,670	22.8	6,432	28,670	22.4
Harris County	5,977	40,670	14.7	7,479	40,670	18.4	7,679	40,670	18.9
Tarrant County	1,635	11,340	14.4	2,104	11,340	18.6	2,190	11,340	19.3

	2020 (COVID-19 pandemic)			2021			2022 (January – September)		
	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>	Persons prescribed PrEP <sup>a</sup>	Persons with PrEP indications <sup>b</sup>	PrEP coverage <sup>c</sup>
	No.	No.	%	No.	No.	%	No.	No.	%
Travis County	5,043	11,590	43.5	5,784	11,590	49.9	5,914	11,590	51.0
<i>Washington</i>									
King County	6,965	17,890	38.9	7,634	17,890	42.7	7,999	17,890	44.7

Abbreviations: PrEP, preexposure prophylaxis; FDA, Food and Drug Administration [footnotes only].

Note. Data for years 2020 and 2021 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.

<sup>a</sup> Estimated by using data from IQVIA pharmacy database reported through September 2022 based on an algorithm that included FDA-approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.

<sup>b</sup> Estimated by using 2017 and 2018 data from National HIV Surveillance System, National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey. Data are rounded to the nearest 10. Data for which values are unknown were not reported; thus, values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. In this table, 2017 denominators were used for 2017 PrEP coverage data; 2018 denominators were used for 2018–2022 PrEP coverage data.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

<sup>d</sup> Number of persons with PrEP indications in San Juan Municipio is not available in 2017. Number of persons with PrEP indications in 2018 is used for 2017 denominator.

<sup>e</sup> Data value <40 was not reported due to unreliability.

**Table 7. Ending the HIV Epidemic Phase I jurisdictions**


Jurisdictions	Territories	States
<i>Arizona</i>	<i>Puerto Rico<sup>a</sup></i>	Alabar
Maricopa County	San Juan Municipio <sup>a</sup>	Arkans
<i>California</i>		Kentuc
Alameda County		Mississi
Los Angeles County		Misso
Orange County		Oklahor
Riverside County		South Caroli
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
<i>District of Columbia</i>		
<i>Florida</i>		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
<i>Georgia</i>		
Cobb County		

Jurisdictions	Territories	States
DeKalb County		
Fulton County		
Gwinnett County		
<i>Illinois</i>		
Cook County		
<i>Indiana</i>		
Marion County		
<i>Louisiana</i>		
East Baton Rouge Parish		
Orleans Parish		
<i>Maryland</i>		
Baltimore City		
Montgomery County		
Prince George's County		
<i>Massachusetts</i>		
Suffolk County		
<i>Michigan</i>		
Wayne County		
<i>Nevada</i>		
Clark County		
<i>New Jersey</i>		
Essex County		
Hudson County		
<i>New York</i>		
Bronx County		
Kings County		
New York County		
Queens County		
<i>North Carolina</i>		
Mecklenburg County		
<i>Ohio</i>		
Cuyahoga County		
Franklin County		
Hamilton County		
<i>Pennsylvania</i>		
Philadelphia County		
<i>Tennessee</i>		
Shelby County		
<i>Texas</i>		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
<i>Washington</i>		
King County		

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].


Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>.


a Linkage to care and viral suppression data are not provided for states and associated jurisdictions that have incomplete reporting of laboratory data to CDC: New Jersey, Pennsylvania (excluding Philadelphia), and Puerto Rico.

**Table 8. Monitoring Ending the HIV Epidemic (EHE) indicators by using data from the National HIV Surveillance System (NHSS) and other reporting systems** 

Indicator	2017 <sup>a</sup>	2018	2019	2020 (COVID-19 Pandemic)	2001
Reduce the estimated number of new HIV infections by 90%	37,000	36,100	34,800	33,600	32,100
Increase the percentage of people living with HIV who know their serostatus to at least 95% (knowledge of HIV status)	85.8	86.4	86.7	87.0	87.3
Reduce the number of new HIV diagnoses by 90% <sup>b</sup>	38,351	37,299	36,421	30,275	35,716
Increase the percentage of persons with newly diagnosed HIV infection linked to HIV medical care within one month of diagnosis to at least 95%	77.8	80.2	81.3	82.4	81.9
Increase the percentage of persons with diagnosed HIV infection who are virally suppressed to at least 95%	63.1	64.7	65.5	64.6	65.9
Increase the percentage of the estimated number of persons with indications for PrEP who have been classified as having been prescribed PrEP to at least 50% (PrEP coverage) <sup>c</sup>	12.7	18.1	22.6	24.7	30.1

Abbreviations: PrEP, preexposure prophylaxis; CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Information on Ending the HIV Epidemic in the U.S. can be found at <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview> .

<sup>a</sup> Baseline data for EHE indicators, published at <https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-1-no-1/cdc-hiv-surveillance-tables-vol-1-no-1.pdf> . Baseline data for PrEP EHE indicator published at <https://www.cdc.gov/hiv/library/reports/surveillance-data-tables/vol-2-no-2/index.html>.

<sup>b</sup> Persons aged  $\geq 13$  years only.

<sup>c</sup> PrEP coverage, reported as a percentage, was calculated as the number of persons classified as having been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Last Reviewed: May 18, 2023